<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism - Li, M - 2023 | Cochrane Library</title> <meta content="Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism - Li, M - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010957.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism - Li, M - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010957.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010957.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism" name="citation_title"/> <meta content="Meixuan Li" name="citation_author"/> <meta content="Jing Li" name="citation_author"/> <meta content="Xiaoqin Wang" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Xu Hui" name="citation_author"/> <meta content="Qi Wang" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Shitong Xie" name="citation_author"/> <meta content="Peijing Yan" name="citation_author"/> <meta content="Sichuan University" name="citation_author_institution"/> <meta content="Jinhui Tian" name="citation_author"/> <meta content="Jianfeng Li" name="citation_author"/> <meta content="Gansu Provincial Hospital" name="citation_author_institution"/> <meta content="Ping Xie" name="citation_author"/> <meta content="Gansu Provincial Hospital" name="citation_author_institution"/> <meta content="Kehu Yang" name="citation_author"/> <meta content="yangkh@lzu.edu.cn" name="citation_author_email"/> <meta content="Liang Yao" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD010957.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/04/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010957.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010957.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010957.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Anticoagulants [therapeutic use]; *Antithrombins [therapeutic use]; *Factor Xa Inhibitors [therapeutic use]; Hemorrhage [chemically induced]; Neoplasm Recurrence, Local [drug therapy]; *Pulmonary Embolism [drug therapy, prevention &amp; control]; *Venous Thromboembolism [prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010957.pub3&amp;doi=10.1002/14651858.CD010957.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010957\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010957\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","pt","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010957.pub3",title:"Oral direct thrombin inhibitors or oral factor Xa inhibitors\\u00A0versus conventional anticoagulants for the treatment of pulmonary embolism",firstPublishedDate:"Apr 14, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010957.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010957.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010957.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010957.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010957.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010957.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010957.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010957.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010957.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010957.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3561 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010957.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-sec-0022"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-sec-0023"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-sec-0077"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/appendices#CD010957-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/supinfo/CD010957StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/supinfo/CD010957StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0004">Meixuan Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0005">Jing Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0006">Xiaoqin Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0007">Xu Hui</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0008">Qi Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0009">Shitong Xie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0010">Peijing Yan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0011">Jinhui Tian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0012">Jianfeng Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0013">Ping Xie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0014"><i class="icon corresponding-author fa fa-envelope"></i>Kehu Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information#CD010957-cr-0015">Liang Yao</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information/en#CD010957-sec-0104">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 April 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010957.pub3">https://doi.org/10.1002/14651858.CD010957.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010957-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010957-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010957-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010957-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010957-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010957-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010957-abs-0004">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010957-abs-0001" lang="en"> <section id="CD010957-sec-0001"> <h3 class="title" id="CD010957-sec-0001">Background</h3> <p>Pulmonary embolism (PE) is a potentially life‐threatening condition in which a clot can migrate from the deep veins, most commonly in the leg, to the lungs. Conventional treatment of PE used unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, and vitamin K antagonists (VKAs). Recently, two forms of direct oral anticoagulants (DOACs) have been developed: oral direct thrombin inhibitors (DTIs) and oral factor Xa inhibitors. DOACs have characteristics that may be favourable to conventional treatment, including oral administration, a predictable effect, no need for frequent monitoring or re‐dosing, and few known drug interactions. This review reports the efficacy and safety of these drugs in the long‐term treatment of PE (minimum duration of three months). This is an update of a Cochrane Review first published in 2015.  </p> </section> <section id="CD010957-sec-0002"> <h3 class="title" id="CD010957-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of oral DTIs and oral factor Xa inhibitors versus conventional anticoagulants for the long‐term treatment of PE. </p> </section> <section id="CD010957-sec-0003"> <h3 class="title" id="CD010957-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases, the World Health Organization International Clinical Trials Registry Platform and the ClinicalTrials.gov trials registers to 2 March 2022. We checked the reference lists of relevant articles for additional studies. </p> </section> <section id="CD010957-sec-0004"> <h3 class="title" id="CD010957-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) in which people with a PE confirmed by standard imaging techniques were allocated to receive an oral DTI or an oral factor Xa inhibitor compared with a conventional anticoagulant or compared with each other for the long‐term treatment of PE (minimum duration three months). </p> </section> <section id="CD010957-sec-0005"> <h3 class="title" id="CD010957-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were recurrent PE, recurrent venous thromboembolism (VTE), and deep vein thrombosis (DVT). Secondary outcomes were all‐cause mortality, major bleeding, and health‐related quality of life. We used GRADE to assess the certainty of evidence for each outcome. </p> </section> <section id="CD010957-sec-0006"> <h3 class="title" id="CD010957-sec-0006">Main results</h3> <p>We identified five additional RCTs with 1484 participants for this update. Together with the previously included trials, we have included ten RCTs with a total of 13,073 participants. Two studies investigated an oral DTI (dabigatran) and eight studies investigated oral factor Xa inhibitors (three rivaroxaban, three apixaban, and two edoxaban). The studies were of good methodological quality overall.  </p> <p>Meta‐analysis showed no clear difference in the efficacy and safety of oral DTI compared with conventional anticoagulation in preventing recurrent PE (odds ratio (OR) 1.02, 95% confidence interval (CI) 0.50 to 2.04; 2 studies, 1602 participants; moderate‐certainty evidence), recurrent VTE (OR 0.93, 95% CI 0.52 to 1.66; 2 studies, 1602 participants; moderate‐certainty evidence), DVT (OR 0.79, 95% CI 0.29 to 2.13; 2 studies, 1602 participants; moderate‐certainty evidence), and major bleeding (OR 0.50, 95% CI 0.15 to 1.68; 2 studies, 1527 participants; moderate‐certainty evidence). We downgraded the certainty of evidence by one level for imprecision due to the low number of events. </p> <p>There was also no clear difference between the oral factor Xa inhibitors and conventional anticoagulation in the prevention of recurrent PE (OR 0.92, 95% CI 0.66 to 1.29; 3 studies, 8186 participants; moderate‐certainty evidence), recurrent VTE (OR 0.83, 95% CI 0.66 to 1.03; 8 studies, 11,416 participants; moderate‐certainty evidence), DVT (OR 0.77, 95% CI 0.48 to 1.25; 2 studies, 8151 participants; moderate‐certainty evidence), all‐cause mortality (OR 1.16, 95% CI 0.79 to 1.70; 1 study, 4817 participants; moderate‐certainty evidence) and major bleeding (OR 0.71, 95% CI 0.36 to 1.41; 8 studies, 11,447 participants; low‐certainty evidence); the heterogeneity for major bleeding was significant (I<sup>2</sup> = 79%). We downgraded the certainty of the evidence to moderate and low because of imprecision due to the low number of events and inconsistency due to clinical heterogeneity. None of the included studies measured health‐related quality of life. </p> </section> <section id="CD010957-sec-0007"> <h3 class="title" id="CD010957-sec-0007">Authors' conclusions</h3> <p>Available evidence shows there is probably little or no difference between DOACs and conventional anticoagulation in the prevention of recurrent PE, recurrent VTE, DVT, all‐cause mortality, and major bleeding. The certainty of evidence was moderate or low. Future large clinical trials are required to identify if individual drugs differ in effectiveness and bleeding risk, and to explore effect differences in subgroups, including people with cancer and obesity. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010957-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010957-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010957-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010957-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010957-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010957-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010957-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010957-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010957-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010957-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010957-abs-0002" lang="en"> <h3>Are direct oral anticoagulants (a type of 'blood thinner') better than traditional anticoagulants for treating a pulmonary embolism (a blood clot in the lung)? </h3> <p><b>What is a pulmonary embolism?</b> </p> <p>A pulmonary embolism occurs when a piece of blood clot breaks off from a clot somewhere else in the body and travels in the blood to the lungs. This can be life‐threatening and occurs in approximately 4 to 12 per 10,000 people. The chances of getting a pulmonary embolism can increase with risk factors, including previous clots, prolonged periods of immobility (such as travelling on aeroplanes or taking bed rest), cancer, exposure to oestrogens (pregnancy, oral contraceptives, or hormone replacement therapy), blood disorders (thrombophilia), and trauma.  </p> <p><b>How is a pulmonary embolism treated?</b> </p> <p>Until recently, the standard treatment for a pulmonary embolism was an anticoagulant: a medicine that either treats or prevents blood clots, often called a 'blood thinner'. Conventional anticoagulants include heparin, fondaparinux, and vitamin K antagonists. However, these drugs can cause side effects and have limitations.  </p> <p>Two types of anticoagulant have been developed: direct thrombin inhibitors (DTIs) and factor Xa inhibitors. These anticoagulants are given orally (that is, by mouth, in the form of a pill), have a predictable effect, do not require frequent monitoring or re‐dosing (taking multiple doses), and have few known interactions with other medicines. For these reasons, direct oral anticoagulants have become the medicines of choice for treating DVT. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if direct oral anticoagulants are useful and safe for treating people with a pulmonary embolism, compared with conventional anticoagulants. We looked at whether 3 months' treatment or longer prevented further blood clots (recurrent deep vein thrombosis (DVT), when a clot forms in a deep vein, usually in the leg), recurrent pulmonary embolism, and pulmonary embolisms. The main safety outcomes included death and unwanted, harmful adverse events, such as major bleeding. </p> <p><b>What did we do?</b> </p> <p>We searched for studies in which people with a pulmonary embolism confirmed by standard imaging techniques were randomly allocated to one of two treatment groups. These types of studies give the most reliable evidence about treatment effects. People in the experimental groups received an oral DTI or an oral factor Xa inhibitor, and their results were compared to the results of people given conventional anticoagulation. All participants were given long‐term treatment of pulmonary embolism (a minimum duration of 3 months).  </p> <p><b>What did we find?</b> </p> <p>After searching for relevant studies, we included 10 studies with a combined total of 13,073 participants. Studies compared oral DTIs and factor Xa inhibitors with conventional anticoagulation. We combined the data from the studies and found that there was no clear difference in the incidence of: </p> <p>‐ recurrent pulmonary embolism;<br/>‐ recurrent deep vein thrombosis (DVT: when a blood clot forms, usually in a deep vein of the leg or pelvis);<br/>‐ recurrent venous thromboembolism (when DVT and pulmonary embolism occur together);<br/>‐ death; <br/>‐ major bleeding </p> <p>This review showed that there was no clear difference between the direct oral anticoagulants and conventional treatment in preventing recurrent PE, recurrent VTE, DVT, mortality, and major bleeding. No study measured health‐related quality of life. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are moderately confident in this evidence. This was because the number of events involved in the studies was small and there were differences in how individual studies were carried out. </p> <p><b>How up to date is this evidence?</b> </p> <p>This review updates a previous Cochrane Review. The evidence is up to date to March 2022. </p> <p><b>Key messages</b> </p> <p>Current evidence shows there is probably little or no difference between direct oral anticoagulants and conventional anticoagulation for preventing recurrent pulmonary embolism, recurrent venous thromboembolism (VTE), deep vein thrombosis (DVT), all‐cause mortality, and major bleeding in people who are being treated for a pulmonary embolism. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010957-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010957-sec-0088"></div> <h3 class="title" id="CD010957-sec-0089">Implications for practice</h3> <section id="CD010957-sec-0089"> <p>Available evidence shows there is little or no difference between direct oral anticoagulants (DOACs) and conventional anticoagulation in the prevention of recurrent pulmonary embolism (PE), recurrent venous thromboembolism (VTE), deep vein thrombosis (DVT), all‐cause mortality, and major bleeding. According to GRADE criteria, the certainty of evidence was moderate to low. DOACs, such as direct thrombin inhibitors (DTIs) and factor Xa inhibitors, may therefore be an alternative to conventional anticoagulation treatment for acute pulmonary embolism. One potential practical advantage of DOACs over conventional anticoagulants is their ease of use due to fixed doses and no need for routine monitoring with blood tests. </p> </section> <h3 class="title" id="CD010957-sec-0090">Implications for research</h3> <section id="CD010957-sec-0090"> <p>There is some evidence of wide inter‐individual variation in anticoagulant effect from the fixed doses of DOACs as currently prescribed. This may be of clinical importance, and further research is needed to compare DOACs directly with one another to see which one is most effective and safe, specifically in relation to bleeding risk in various subgroups, such as in people with cancer or obesity. Such studies would need to be very large and may not be considered financially viable to sponsoring drug companies. Any impact on the decision to use extended phase anticoagulation and interruption of procedures with DOAC use should also be investigated. Further research is also required to establish other factors associated with the use of DOACs, such as adherence, quality of life, cost‐effectiveness, and tolerability. Finally, research is required in categories of venous thrombosis not specifically examined in the studies included here, such as in people with malignancy or a thrombophilic abnormality, as well as travel‐associated venous thrombosis. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010957-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010957-sec-0008"></div> <div class="table" id="CD010957-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation for the treatment of pulmonary embolism</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation for the treatment of pulmonary embolism</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with a pulmonary embolism, confirmed by standard imaging techniques<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> oral DTIs<br/><b>Comparison:</b> conventional anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with conventional anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oral DTI</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent PE</b><sup>a</sup> </p> <p> </p> <p>Follow‐up: </p> <p>6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.02</b><br/>(0.50 to 2.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1602<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data from <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(10 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b><sup>c</sup> </p> <p> </p> <p>Follow‐up: </p> <p>6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.93</b><br/>(0.52 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1602<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data from <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(16 to 50) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><sup>d</sup> </p> <p> </p> <p>Follow‐up: </p> <p>6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.79</b><br/>(0.29 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1602<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data from <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(3 to 23) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> did not report on all‐cause mortality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><sup>e</sup> </p> <p> </p> <p>Follow‐up: </p> <p>6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.50</b><br/>(0.15 to 1.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1527<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data from <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(2 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> did not measure health‐related quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CTPA:</b> computed tomographic pulmonary angiography; <b>DVT</b> : deep vein thrombosis; <b>ISTH</b> : International Society on Thrombosis and Haemostasis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>V/Q:</b> ventilation/perfusion; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate, the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited, the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Confirmed by V/Q lung scanning, pulmonary angiography, or CTPA<br/><sup>b</sup>We downgraded one level for imprecision due to the low number of events. The possibility of publication bias is not excluded but we did not consider it sufficient to downgrade the certainty of evidence.<br/><sup>c</sup>VTE includes clinically overt DVT and PE. Clinically overt DVT, confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, proximal compression ultrasound); or clinically overt PE, confirmed by V/Q lung scanning, pulmonary angiography, or CTPA.<br/><sup>d</sup>Clinically overt DVT confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, proximal compression ultrasound). <br/><sup>e</sup>As defined by the ISTH (<a href="./references#CD010957-bbs2-0111" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>): 1. Fatal bleeding, and/or 2. symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra‐articular or pericardial, or intramuscular with compartment syndrome, and/or 3. bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or packed red cells. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010957-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation for the treatment of pulmonary embolism</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Oral factor Xa inhibitors versus conventional anticoagulation for the treatment of pulmonary embolism</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with a pulmonary embolism, confirmed by standard imaging techniques<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> oral factor Xa inhibitors<br/><b>Comparison:</b> conventional anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk with conventional<b> </b> anticoagulation </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oral factor Xa inhibitors</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent PE</b><sup>a</sup> </p> <p> </p> <p>Follow‐up: </p> <p>0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.92</b><br/>(0.66 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8186<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b </sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(12 to 23) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b><sup>c</sup> </p> <p> </p> <p>Follow‐up: </p> <p>0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.83</b><br/>(0.66 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,416<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 of 8 studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/>(21 to 33) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><sup>d</sup> </p> <p> </p> <p>Follow‐up: </p> <p>5 days to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.77</b><br/>(0.48 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8151<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/>(5 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p> </p> <p>Follow‐up: </p> <p>0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.16</b><br/>(0.79 to 1.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4817<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(16 to 35) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><sup>e</sup> </p> <p> </p> <p>Follow‐up: </p> <p>0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.71</b><br/>(0.36 to 1.41)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,447<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 of 8 studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(8 to 32) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies did not measure health‐related quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CTPA:</b> computed tomographic pulmonary angiography; <b>DVT:</b> deep vein thrombosis; <b>ISTH:</b> International Society on Thrombosis and Haemostasis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>V/Q:</b> ventilation/perfusion; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate, the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited, the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate, the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Confirmed by V/Q lung scanning, pulmonary angiography, or CTPA.<br/><sup>b</sup>We downgraded one level for imprecision due to the low number of events. The possibility of publication bias is not excluded but we did not consider it sufficient to downgrade the certainty of evidence.<br/><sup>c</sup>VTE includes clinically overt DVT and PE. Clinically overt DVT, confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, proximal compression ultrasound); or clinically overt PE, confirmed by V/Q lung scanning, pulmonary angiography, or CTPA.<br/><sup>d</sup>Clinically overt DVT confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, proximal compression ultrasound). <br/><sup>e</sup>As defined by the ISTH (<a href="./references#CD010957-bbs2-0111" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>): 1. Fatal bleeding, and/or 2. symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra‐articular or pericardial, or intramuscular with compartment syndrome, and/or 3. bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or packed red cells.<br/><sup>f</sup>We downgraded one level for serious inconsistency (I<sup>2</sup> = 79% due to clinical heterogeneity). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010957-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010957-sec-0009"></div> <section id="CD010957-sec-0010"> <h3 class="title" id="CD010957-sec-0010">Description of the condition</h3> <p>Pulmonary embolism (PE) is a potentially life‐threatening condition in which a blood clot blocks the supply of blood to the lungs. PE is often a consequence of a thrombus in the deep veins of the legs (deep vein thrombosis, DVT) that dislodges and migrates in the blood to the pulmonary arteries. The incidence of PE has been estimated as 4 to 12 per 10,000 people annually (<a href="./references#CD010957-bbs2-0091" title="KellerK , HobohmL , EbnerM , KresojaKP , MunzelT , KonstantinidesSV , et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolismin Germany. European Heart Journal2020;41:522-9.">Keller 2020</a>; <a href="./references#CD010957-bbs2-0092" title="KonstantinidesSV , MeyerG , BecattiniC , BuenoH , GeersingGJ , HarjolaVP , et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal2020;41(4):543-603.">Konstantinides 2020</a>; <a href="./references#CD010957-bbs2-0126" title="WendelboeAM , RaskobGE . Global burden of thrombosis: epidemiologic aspects. Circulation Research2016;118:1340-7.">Wendelboe 2016</a>), and longitudinal studies have revealed that the annual PE prevalence rates tend to rise over time (<a href="./references#CD010957-bbs2-0069" title="DentaliF , AgenoW , PomeroF , FenoglioL , SquizzatoA , BonziniM . Timetrends and case fatality rate of in-hospital treated pulmonary embolism during11 years of observation in Northwestern Italy. Thrombosis and Haemostasis2016;115:399-405.">Dentali 2016</a>; <a href="./references#CD010957-bbs2-0066" title="deMiguel-DiezJ , Jimenez-GarciaR , JimenezD , MonrealM , GuijarroR , OteroR , et al. Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. European Respiratory Journal2014;44:942-50.">de Miguel‐Diez 2014</a>; <a href="./references#CD010957-bbs2-0091" title="KellerK , HobohmL , EbnerM , KresojaKP , MunzelT , KonstantinidesSV , et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolismin Germany. European Heart Journal2020;41:522-9.">Keller 2020</a>; <a href="./references#CD010957-bbs2-0096" title="LehnertP , LangeT , MollerCH , OlsenPS , CarlsenJ . Acute pulmonary embolismin a national Danish cohort: increasing incidence and decreasing mortality. Thrombosis and Haemostasis2018;118:539-46.">Lehnert 2018</a>). DVT is present in approximately 70% to 80% of people with PE, yet only 15% of PE cases have symptoms of DVT (<a href="./references#CD010957-bbs2-0085" title="HuertaC , JohanssonS , WallanderMA , Garcia RodriguezLA . Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine2007;167(9):935-43.">Huerta 2007</a>). One long‐term complication of PE is chronic thromboembolic pulmonary hypertension (CTPH). CTPH occurs when the clot obstructs the pulmonary arteries, causing excessive pressure in the pulmonary artery and stress to the right ventricle. CTPH is uncommon but it can result in heart failure (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). It is estimated that up to a quarter of all PE patients present with sudden death (<a href="./references#CD010957-bbs2-0080" title="HeitJA . Epidemiology of venous thromboembolism. Nature Reviews Cardiology2015;12(8):464-74.">Heit 2015</a>). In the USA, PE is one of the leading causes of cardiovascular mortality, contributing to nearly 300,000 deaths annually (<a href="./references#CD010957-bbs2-0126" title="WendelboeAM , RaskobGE . Global burden of thrombosis: epidemiologic aspects. Circulation Research2016;118:1340-7.">Wendelboe 2016</a>). </p> <p>Risk factors for PE are similar to those for DVT and are classified as provoked or unprovoked (<a href="./references#CD010957-bbs2-0089" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e419S-94S.">Kearon 2012</a>). For unprovoked PE, no clear precipitating risk factor can be identified; risk factors are either hereditary or more often acquired. For provoked PE, risk factors include cancer, acute medical illness, surgery, trauma, immobility (often in hospital and lasting at least three days), obesity, inflammatory diseases/infection, hormone therapy (oestrogen‐containing), pregnancy (particularly the postpartum period), long‐distance travel, recent hospitalisation, and antiphospholipid syndrome (APS) (<a href="./references#CD010957-bbs2-0086" title="KakkosSK , GohelM , BaekgaardN , BauersachsR , Bellmunt-MontoyaS , BlackSA , et al. European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. European Journal of Vascular and Endovascular Surgery2021;61(1):9-82.">Kakkos 2021</a>). </p> <p>People presenting with signs or symptoms of PE, such as chest pain, shortness of breath, or coughing up blood, will have their general medical history assessed, undergo a physical examination, and may be offered a chest X‑ray to exclude other causes (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). However, it can be particularly challenging to diagnose PE as the symptoms (dyspnoea, pleuritic chest pain, retrosternal chest pain, cough, and haemoptysis) are not specific (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). In severe cases, right ventricle failure leads to dizziness, syncope, tachypnoea, tachycardia, hypoxia, elevated jugular venous pressure, systemic hypotension, and cardiogenic shock (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). The UK National Institute for Health and Care Excellence (NICE) recommends that people presenting with suspected PE should be assessed using a two‐level PE Wells score (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>; <a href="./references#CD010957-bbs2-0125" title="WellsPS , AndersonDR , RodgerM , GinsbergJS , KearonC , GentM , et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thrombosis and Haemostasis2000;83(3):416-20.">Wells 2000</a>). Points are awarded for the presence of clinical features, including clinical signs and symptoms of DVT (minimum of leg swelling and pain with palpation of the deep veins), heart rate greater than 100 beats per minute, immobilisation for more than three days or surgery in the previous four weeks, previous DVT/PE, haemoptysis, and malignancy (on treatment, treated in the last six months, or palliative) (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). For people with a low pre‐test probability, the use of a D‐dimer assay combined with a clinical prediction rule has a high negative predictive value and avoids the need for unnecessary imaging (<a href="./references#CD010957-bbs2-0105" title="QaseemA , SnowV , BarryPE , HornbakeR , RodnickJE , TobolicT , et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Annals of Internal Medicine2007;146(6):454-8.">Qaseem 2007</a>). However, for people who have an intermediate or high pre‐test probability of PE, imaging is essential. People with a score of greater than four are judged to be likely to have had a PE and should undergo immediate diagnostic imaging. If this cannot be performed immediately, patients should be given immediate interim parenteral anticoagulant therapy until the imaging test is done. Those with a negative diagnosis in whom a DVT is likely should be given a proximal leg vein ultrasound scan (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). </p> <p>There are three types of imaging techniques used to diagnose PE: computed tomography pulmonary angiogram (CTPA), ventilation‐perfusion (V/Q) scan, and pulmonary angiography. </p> <p>CTPA involves injecting a contrast agent intravenously and performing a computed tomography (CT) scan of the chest to visualise the pulmonary arteries and detect any thrombi in the pulmonary arteries down to the subsegmental branches. The procedure has over 90% specificity and sensitivity in diagnosing PE in the main, lobar, and segmental pulmonary arteries (<a href="./references#CD010957-bbs2-0107" title="RiedelM . Diagnosing pulmonary embolism. Postgraduate Medicine Journal2004;80(944):309-19.">Riedel 2004</a>). However, the radiation dose administered to the individual is much larger than that of a V/Q scan, and thus people who have a CTPA may be at an increased lifetime risk of cancer (<a href="./references#CD010957-bbs2-0054" title="AndersonDR , BarnesDC . Computerized tomographic pulmonary angiography versus ventilation perfusion lung scanning for the diagnosis of pulmonary embolism. Current Opinion in Pulmonary Medicine2009;15(5):425-9.">Anderson 2009</a>). CTPA use is limited in people with iodine allergy, hyperthyroidism, those who are pregnant and breastfeeding, and is contraindicated in people with severe renal failure (<a href="./references#CD010957-bbs2-0092" title="KonstantinidesSV , MeyerG , BecattiniC , BuenoH , GeersingGJ , HarjolaVP , et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal2020;41(4):543-603.">Konstantinides 2020</a>). </p> <p>A V/Q scan comprises two parts: the ventilation part, where the patient breathes in a radioisotope (in the form of a gas or an aerosol) and the perfusion part, where the patient is given an intravenous injection of the isotope. A gamma camera is used to detect where the isotopes are in the lungs and the images show which areas of the lungs are ventilated but not perfused (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). Another version of this test, the V/Q single photon emission computed tomography (V/Q SPECT) has been developed. The camera is rotated around the patient, thus generating three‐dimensional images and leading to a more accurate diagnosis (<a href="./references#CD010957-bbs2-0093" title="LaurenceIJ , RedmanSL , CorriganAJ , GrahamRN . V/Q SPECT imaging of acute pulmonary embolus - a practical perspective. Clinical Radiology2012;67(10):941-8.">Laurence 2012</a>). </p> <p>Pulmonary angiography is an imaging method that uses x‐rays and a special dye to see how blood flows through the lung. The procedure is invasive, with related risks of mortality and complications, especially for people with haemodynamic compromise or respiratory failure (<a href="./references#CD010957-bbs2-0117" title="SteinPD , AthanasoulisC , AlaviA , GreenspanRH , HalesCA , SaltzmanHA , et al. Complications and validity of pulmonary angiography in acute pulmonary embolism. Circulation1992;85(2):462-8.">Stein 1992</a>). For several decades, pulmonary angiography was the "gold standard" for diagnosing or ruling out acute PE, but it is now rarely used because less‐invasive CTPA provides comparable diagnostic accuracy (<a href="./references#CD010957-bbs2-0092" title="KonstantinidesSV , MeyerG , BecattiniC , BuenoH , GeersingGJ , HarjolaVP , et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal2020;41(4):543-603.">Konstantinides 2020</a>). </p> </section> <section id="CD010957-sec-0011"> <h3 class="title" id="CD010957-sec-0011">Description of the intervention</h3> <p>Conventional treatment of PE used unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, or vitamin K antagonists (VKAs). These drugs block the action of thrombin either by "activating naturally occurring thrombin inhibitors or by inhibiting specific factors in the coagulation system that subsequently impact on thrombin generation or activity" (<a href="./references#CD010957-bbs2-0124" title="WeitzJI . A novel approach to thrombin inhibition. Thrombosis Research2003;109(Suppl 1):S17-22.">Weitz 2003</a>). Although heparins and VKAs are effective anticoagulants, there are limitations associated with each. LMWH must be administered parenterally and may be associated with an increased risk of bleeding, loss of bone strength, elevated liver enzymes, and heparin‐induced thrombocytopenia (<a href="./references#CD010957-bbs2-0092" title="KonstantinidesSV , MeyerG , BecattiniC , BuenoH , GeersingGJ , HarjolaVP , et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal2020;41(4):543-603.">Konstantinides 2020</a>). Meanwhile, VKAs have a narrow therapeutic window, require frequent monitoring and dosage adjustments, and can have multiple interactions with other drugs (<a href="./references#CD010957-bbs2-0051" title="AgenoW , GallusAS , WittkowskyA , CrowtherM , HylekEM , PalaretiG , et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(Suppl 2):e44S-88S.">Ageno 2012</a>). </p> <p>Two further classes of oral anticoagulants have been developed: direct thrombin inhibitors (DTIs) and factor Xa inhibitors. DTIs and factor Xa inhibitors have characteristics that may be favourable to heparin and VKAs, including ease of oral administration, a predictable effect, lack of frequent monitoring or re‐dosing, and fewer known drug interactions (compared with VKA) (<a href="./references#CD010957-bbs2-0075" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a>).   </p> <p>The latest American College of Chest Physicians (ACCP) guidelines recommended apixaban, dabigatran, edoxaban, or rivaroxaban over VKAs as treatment‐phase (first three months) anticoagulant therapy for people with VTE (DVT of the leg or PE); and recommended an oral Xa inhibitor (apixaban, edoxaban, rivaroxaban) over LMWH for the initiation and treatment phases of therapy for acute VTE associated with cancer (<a href="./references#CD010957-bbs2-0090" title="KearonC , AklEA , OrnelasJ , BlaivasA , JimenezD , BounameauxH , et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest2016;149(2):315-52.">Kearon 2016</a>; <a href="./references#CD010957-bbs2-0118" title="StevensSM , WollerSC , Baumann KreuzigerL , BounameauxH , DoerschugK , GeersingGJ , et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):2247-59.">Stevens 2021</a>). Similarly, the 2019 European Society of Cardiology (ESC) guidelines recommended DOACs in preference to VKAs in eligible individuals ready for an oral anticoagulant (<a href="./references#CD010957-bbs2-0092" title="KonstantinidesSV , MeyerG , BecattiniC , BuenoH , GeersingGJ , HarjolaVP , et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal2020;41(4):543-603.">Konstantinides 2020</a>). The <a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a> guidelines recommend offering either apixaban or rivaroxaban as initial choices, and suggested other regimens only for people suitable for neither: consider a DOAC for people with active cancer and confirmed proximal DVT or PE, and consider other strategies when DOAC is unsuitable.  </p> <p>According to research by Lutsey and colleagues, the use of DOACs (especially rivaroxaban and apixaban) to treat VTE has increased dramatically in the USA since the US Food and Drug Administration (FDA) approved them for this application (<a href="./references#CD010957-bbs2-0098" title="LutseyPL , WalkerRF , MacLehoseRF , AlonsoA , AdamTJ , ZakaiNA . Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. Research and Practice in Thrombosis and Haemostasis2019;3(4):668-73.">Lutsey 2019</a>). Drawing on individual health insurance data for 2012 to 2017, they found that DOACs accounted for less than 2% of the prescriptions for VTE treatment at the beginning of 2012 and increased to more than 80% by the fourth quarter of 2017 (<a href="./references#CD010957-bbs2-0098" title="LutseyPL , WalkerRF , MacLehoseRF , AlonsoA , AdamTJ , ZakaiNA . Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. Research and Practice in Thrombosis and Haemostasis2019;3(4):668-73.">Lutsey 2019</a>). </p> </section> <section id="CD010957-sec-0012"> <h3 class="title" id="CD010957-sec-0012">How the intervention might work</h3> <section id="CD010957-sec-0013"> <h4 class="title">Oral direct thrombin inhibitors</h4> <p>DTIs work by binding directly to the enzyme thrombin without the need for a co‐factor, such as antithrombin. Unlike heparins and VKAs, DTIs can inhibit both soluble thrombin and fibrin‐bound thrombin (<a href="./references#CD010957-bbs2-0087" title="KamPC , KaurN , ThongCL . Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia2005;60(6):565-74.">Kam 2005</a>). Other advantages include a more predictable anticoagulant effect because of their lack of binding to other proteins, lack of an antiplatelet effect, and no suspected concern of heparin‐induced thrombocytopenia (HIT) (<a href="./references#CD010957-bbs2-0094" title="LeeCJ , AnsellJE . Direct thrombin inhibitors. British Journal of Clinical Pharmacology2011;72(4):581-92.">Lee 2011</a>). There are several types of DTIs. </p> <section id="CD010957-sec-0014"> <h5 class="title">Dabigatran</h5> <p>Dabigatran etexilate is a reversible oral DTI that is metabolised to its active ingredient, dabigatran, in the gastrointestinal tract (<a href="./references#CD010957-bbs2-0051" title="AgenoW , GallusAS , WittkowskyA , CrowtherM , HylekEM , PalaretiG , et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(Suppl 2):e44S-88S.">Ageno 2012</a>). It does not require anticoagulation monitoring, is excreted by the kidneys, and has a half‐life of 12 to 17 hours. As well as a treatment for venous thrombosis, this drug has been involved in many large randomised studies of atrial fibrillation (<a href="./references#CD010957-bbs2-0064" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139-51.">Connolly 2009</a>), acute coronary syndromes (<a href="./references#CD010957-bbs2-0102" title="OldgrenJ , BudajA , GrangerCB , KhderY , RobertsJ , SiegbahnA , et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal2011;32(22):2781-9.">Oldgren 2011</a>), prevention of thrombosis following orthopaedic surgery (<a href="./references#CD010957-bbs2-0072" title="ErikssonBI , DahlOE , RosenecherN , KurthaAA , vanDijkCN , FrostickSP , et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis2007;5(11):2178-85.">Eriksson 2007</a>), and in people with mechanical heart valves (<a href="./references#CD010957-bbs2-0120" title="Van de WerfF , BrueckmannM , ConnollySJ , FriedmanJ , GrangerCB , HartterS , et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). American Heart Journal2012;163(6):931-7.">Van de Werf 2012</a>). In common with the other DOACs, dabigatran is associated with a lower incidence of intracranial haemorrhage (compared with VKAs). However, again compared with VKAs, dabigatran showed a higher incidence of indigestion and heartburn and a higher incidence of gastrointestinal bleeding (<a href="./references#CD010957-bbs2-0057" title="BaetzBE , SpinlerSA . Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy2008;28(11):1354-73.">Baetz 2008</a>). For the treatment of PE in people with creatinine clearance (CrCL) of more than 30 mL/min, the recommended dosage of dabigatran is 150 mg twice daily following at least five days of initial therapy with a parenteral anticoagulant. For people aged 80 years or older and for people having verapamil, the recommended dose is 110 mg twice daily. In people aged 75 to 80 years, people with moderately reduced kidney function, people with gastritis, oesophagitis or gastro‐oesophageal reflux, and people at increased risk of bleeding, either dose (300 mg or 220 mg) can be given, based on an individual assessment. Dabigatran is not recommended in people with CrCL of less than 30 mL/min (<a href="./references#CD010957-bbs2-0092" title="KonstantinidesSV , MeyerG , BecattiniC , BuenoH , GeersingGJ , HarjolaVP , et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal2020;41(4):543-603.">Konstantinides 2020</a>; <a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>).  </p> </section> <section id="CD010957-sec-0015"> <h5 class="title">Ximelagatran</h5> <p>Ximelagatran is a prodrug that is metabolised to melagatran as it is better absorbed from the gastrointestinal tract (<a href="./references#CD010957-bbs2-0087" title="KamPC , KaurN , ThongCL . Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia2005;60(6):565-74.">Kam 2005</a>). It has a plasma half‐life of three hours, has a predictable response after oral administration, and does not require coagulation monitoring. Ximelagatran was found to be effective in the treatment of venous thromboembolism but caused unacceptable liver toxicity (<a href="./references#CD010957-bbs2-0059" title="BoudesPF . The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemporary Clinical Trials2006;27(5):432-40.">Boudes 2006</a>), and, therefore, was never licensed. For the treatment of PE, the usual dosing of ximelagatran for adults is 48 mg twice daily (<a href="./references#CD010957-bbs2-0084" title="HoSJ , BrightonTA . Ximelagatran: direct thrombin inhibitor. Vascular Health and Risk Management2006;2(1):49-58.">Ho 2006</a>). </p> </section> </section> <section id="CD010957-sec-0016"> <h4 class="title">Oral factor Xa inhibitors</h4> <p>Factor Xa inhibitors bind directly to the active site of factor Xa, thus blocking the activity of the clotting factor. Unlike indirect factor Xa inhibitors such as fondaparinux, direct factor Xa inhibitors "inactivate free FXa and FXa incorporated with the prothrombinase complex equally well" and do not require interaction with the inhibitor antithrombin (<a href="./references#CD010957-bbs2-0073" title="ErikssonBI , QuinlanDJ , WeitzJI . Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinetics2009;48(1):1-22.">Eriksson 2009</a>). They have been shown to be non‐inferior to VKAs but without the need for regular blood test monitoring. They appear to have fewer drug interactions (compared with VKAs) and no food or alcohol interactions. </p> <section id="CD010957-sec-0017"> <h5 class="title">Rivaroxaban</h5> <p>Rivaroxaban is a reversible direct factor Xa inhibitor. The plasma half‐life is estimated to be eight to 10 hours if renal function is normal (<a href="./references#CD010957-bbs2-0116" title="SpyropoulosAC , DouketisJD . How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood2012;120(15):2954-62.">Spyropoulos 2012</a>). For the treatment of PE, the recommended dosage of rivaroxaban is 15 mg twice daily for the first 21 days followed by 15 mg once daily in people with moderate (CrCL 30 mL/min to 49 mL/min) or severe (CrCL 15 mL/min to 29 ml/min) renal impairment, if their risk of bleeding outweighs the risk of recurrent DVT or PE (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>).  </p> </section> <section id="CD010957-sec-0018"> <h5 class="title">Apixaban</h5> <p>Apixaban is an oral, small molecule, reversible inhibitor of factor Xa with a plasma half‐life of eight to 15 hours. For the treatment of PE, the recommended dosage of apixaban is 10 mg twice daily for the first seven days followed by 5 mg twice daily for continued treatment (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). For people with severe renal impairment (CrCL 15 mL/min to 29 mL/min), apixaban should be used with caution (<a href="./references#CD010957-bbs2-0073" title="ErikssonBI , QuinlanDJ , WeitzJI . Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinetics2009;48(1):1-22.">Eriksson 2009</a>).  </p> </section> <section id="CD010957-sec-0019"> <h5 class="title">Betrixaban</h5> <p>Betrixaban is an orally administered direct factor Xa inhibitor. It has a half‐life of 19 to 27 hours (<a href="./references#CD010957-bbs2-0104" title="PalladinoM , MerliG , ThomsonL . Evaluation of the oral direct factor Xa inhibitor - betrixaban. Expert Opinion on Investigational Drugs2013;22(11):1465-72.">Palladino 2013</a>). For the prophylaxis of PE, the recommended dose of betrixaban is an initial single dose of 160 mg starting on day 1, followed by 80 mg once daily, taken for 35 to 42 days at the same time each day with food. For people with severe renal impairment (CrCL 15 mL/min to 30 mL/min computed by Cockcroft‐Gault using actual body weight), the recommended dose of betrixaban is an initial single dose of 80 mg followed by 40 mg once daily (<a href="./references#CD010957-bbs2-0074" title="FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. fda.gov/drugs/resources-information-approved-drugs/fda-approved-betrixaban-bevyxxa-portola-prophylaxis-venous-thromboembolism-vte-adult-patients (accessed 13 December 2022).">FDA 2017</a>).  </p> </section> <section id="CD010957-sec-0020"> <h5 class="title">Edoxaban</h5> <p>Edoxaban is an oral direct inhibitor of activated factor X that is rapidly absorbed with a half‐life of nine to 11 hours. Edoxaban has a dual mechanism of elimination with one‐third eliminated via the kidneys and the remainder excreted in the faeces (<a href="./references#CD010957-bbs2-0070" title="EikelboomJW , WeitzJI . Update on antithrombotic therapy: new anticoagulants. Circulation2010;121(13):1523-32.">Eikelboom 2010</a>). For the treatment of PE, the recommended dose of edoxaban is 60 mg taken orally once daily following at least five days of initial therapy with a parenteral anticoagulant. The edoxaban dose should be reduced to 30 mg once daily in people with CrCL 15 mL/min to 50 mL/min, those who weigh less than or equal to 60 kg, or those who are taking certain concomitant P‐glycoprotein inhibitor medications (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). </p> </section> </section> </section> <section id="CD010957-sec-0021"> <h3 class="title" id="CD010957-sec-0021">Why it is important to do this review</h3> <p>The efficacy and safety of oral DTIs and oral factor Xa inhibitors for the treatment of VTE has been examined in several randomised controlled trials (the EINSTEIN‐PE study (<a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>), the ODIXa‐DVT study (<a href="./references#CD010957-bbs2-0052" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116(2):180-7.">Agnelli 2007</a>), the Botticelli study (<a href="./references#CD010957-bbs2-0058" title="Botticelli Investigators, Writing Committee, BüllerH , DeitchmanD , PrinsM , SegersA , et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6(8):1313-8.">Botticelli Investigators 2008</a>), the AMPLIFY study (<a href="./references#CD010957-bbs2-0053" title="AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808.">Agnelli 2013</a>), the RE‐COVER II study (<a href="./references#CD010957-bbs2-0112" title="SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118:Abstract 205.">Schulman 2011</a>), and the THRIVE studies (<a href="./references#CD010957-bbs2-0071" title="ErikssonH , WåhlanderK , GustafssonD , WelinLT , FrisonL , SchulmanS , et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis2003;1(1):41-7.">Eriksson 2003</a>)). Several non‐Cochrane systematic reviews have examined the benefits and harms of DTIs and factor Xa inhibitors versus VKAs in the treatment of acute VTE (<a href="./references#CD010957-bbs2-0075" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a>; <a href="./references#CD010957-bbs2-0109" title="SamaranayakeCB , AndersonJ , McCabeC , ZahirSF , W UphamJ , KeirG . Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis. Internal Medicine Journal2022;52(2):272-81.">Samaranayake 2022</a>; <a href="./references#CD010957-bbs2-0115" title="SongX , LiuZ , ZengR , ShaoJ , LiuB , ZhengY , et al. Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs). Annals of Translational Medicine2021;9(2):162.">Song 2021</a>; <a href="./references#CD010957-bbs2-0127" title="WuO , MorrisS , LarsenTB , SkjøthF , EvansA , BowrinK , et al. Effectiveness and safety of nonvitamin K oral anticoagulants rivaroxaban and apixaban in patients with venous thromboembolism: a meta-analysis of real-world studies. Cardiovascular Therapeutics2022;2022:2756682.">Wu 2022</a>). However, specific data on people with PE were not reported, and appropriate subgroup analyses that considered some clinical factors (such as the history of VTE, age, and active cancer) were lacking. It is important to assess the efficacy and safety of oral DTIs and oral factor Xa inhibitors for the treatment of PE to help both healthcare professionals and people with PE choose the most appropriate treatment. Since the first version of this review was completed (<a href="./references#CD010957-bbs2-0129" title="RobertsonL , KestevenP , McCaslinJE . Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews2015, Issue 12. Art. No: CD010957. [DOI: 10.1002/14651858.CD010957.pub2]">Robertson 2015a</a>), several new RCTs have been published (<a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>). Thus, it is necessary to update the review and present the most up‐to‐date evidence to aid decision‐making in clinical practice. For this update, due to the limited number of included studies, subgroup analyses were only possible for active cancer and the different types of factor Xa inhibitors. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010957-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010957-sec-0022"></div> <p>To assess the efficacy and safety of oral DTIs and oral factor Xa inhibitors versus conventional anticoagulants for the long‐term treatment of PE. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010957-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010957-sec-0023"></div> <section id="CD010957-sec-0024"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010957-sec-0025"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) in which participants with a confirmed pulmonary embolism (PE) were allocated to receive an oral direct thrombin inhibitor (DTI) or an oral factor Xa inhibitor for the treatment of PE. We included studies published and in progress if preliminary results were available. We placed no restrictions on publication status and non‐English studies were eligible for inclusion in the review. We excluded DTIs and factor Xa inhibitors that were not given by the oral route. </p> </section> <section id="CD010957-sec-0026"> <h4 class="title">Types of participants</h4> <p>We included participants with a PE, confirmed by standard imaging techniques (CTPA, V/Q scan, or pulmonary angiography). </p> </section> <section id="CD010957-sec-0027"> <h4 class="title">Types of interventions</h4> <p>We included the following interventions:</p> <p> <ul id="CD010957-list-0001"> <li> <p>oral DTIs (e.g. dabigatran, ximelagatran) (although ximelagatran was withdrawn from the market in 2006 due to safety issues, we included it in the review to make the results as comprehensive as possible); </p> </li> <li> <p>oral factor Xa inhibitors (e.g. rivaroxaban, apixaban, betrixaban, edoxaban);</p> </li> <li> <p>other anticoagulants (e.g. LMWH, UFH, VKAs).</p> </li> </ul> </p> <p>We included the following comparisons:</p> <p> <ul id="CD010957-list-0002"> <li> <p>one oral DTI versus another oral DTI;</p> </li> <li> <p>one oral factor Xa inhibitor versus another oral factor Xa inhibitor;</p> </li> <li> <p>oral DTI versus oral factor Xa inhibitor;</p> </li> <li> <p>oral DTI or oral factor Xa inhibitor versus another anticoagulant.</p> </li> </ul> </p> <p>Treatment had to be for a minimum duration of three months as this is conventional anticoagulation practice for a PE. </p> </section> <section id="CD010957-sec-0028"> <h4 class="title">Types of outcome measures</h4> <section id="CD010957-sec-0029"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010957-list-0003"> <li> <p>Recurrent PE, confirmed by standard imaging techniques (CTPA, V/Q scan, or pulmonary angiography) </p> </li> <li> <p>Recurrent venous thromboembolism (VTE, clinically overt DVT, confirmed by standard imaging techniques, including venography, impedance plethysmography, whole‐leg compression ultrasound, or proximal compression ultrasound; or clinically overt PE, confirmed by CTPA, V/Q scan, or pulmonary angiography) </p> </li> <li> <p>Clinically overt DVT, confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, or proximal compression ultrasound). </p> </li> </ul> </p> </section> <section id="CD010957-sec-0030"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010957-list-0004"> <li> <p>All‐cause mortality</p> </li> <li> <p>Adverse effects of treatment, including major bleeding (as defined by the International Society on Thrombosis and Haemostasis (ISTH); <a href="./references#CD010957-bbs2-0111" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>): </p> <ul id="CD010957-list-0005"> <li> <p>fatal bleeding;</p> </li> <li> <p>symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra‐articular or pericardial, or intramuscular with compartment syndrome; </p> </li> <li> <p>bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or packed red cells; </p> </li> <li> <p>any combination of the three points above.</p> </li> </ul> </li> <li> <p> Health‐related quality of life, as reported in included studies</p> </li> </ul> </p> </section> </section> </section> <section id="CD010957-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010957-sec-0032"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases, from inception to 2 March 2022, for RCTs and controlled clinical trials without language, publication year, or publication status restrictions: </p> <p> <ul id="CD010957-list-0006"> <li> <p>the Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web);</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2022 via the Cochrane Register of Studies Online (CRSO); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE); </p> </li> <li> <p>Embase Ovid;</p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature) Ebsco.</p> </li> </ul> </p> <p>We developed search strategies for other databases from the search strategy designed for MEDLINE. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by Cochrane for identifying RCTs and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions </i>Chapter 4, <a href="./references#CD010957-bbs2-0095" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , MetzendorfMI , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Available from training.cochrane.org/handbook.">Lefebvre 2021</a>). Search strategies for major databases are provided in <a href="./appendices#CD010957-sec-0094">Appendix 1</a>. </p> <p>We searched the following trials registries:</p> <p> <ul id="CD010957-list-0007"> <li> <p>the World Health Organization International Clinical Trials Registry Platform (who.int/trialsearch);</p> </li> <li> <p>ClinicalTrials.gov (clinicaltrials.gov).</p> </li> </ul> </p> <p>The most recent searches were carried out on 2 March 2022.</p> </section> <section id="CD010957-sec-0033"> <h4 class="title">Searching other resources</h4> <p>We reviewed the reference lists of relevant articles for potential additional citations.</p> </section> </section> <section id="CD010957-sec-0034"> <h3 class="title" id="CD010957-sec-0034">Data collection and analysis</h3> <section id="CD010957-sec-0035"> <h4 class="title">Selection of studies</h4> <p>We used Covidence to screen retrieved records (<a href="./references#CD010957-bbs2-0065" title="Covidence. Version accessed 23 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>). Seven review authors (ML, JL, XH, LY, XW, QW, SX), working in pairs, independently screened all titles and abstracts based on the specified inclusion and exclusion criteria, and then reviewed full‐text records of all potentially eligible articles. We linked together multiple reports of the same study and used the most comprehensive report as the primary reference. We resolved any disagreements by discussion. We illustrated the study selection process in a PRISMA diagram (<a href="./references#CD010957-bbs2-0103" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372:n71.">Page 2021</a>). We listed studies excluded after full‐text assessment in the <a href="./references#CD010957-sec-0111" title="">Characteristics of excluded studies</a> table, and provided the reasons for exclusion. </p> </section> <section id="CD010957-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Six review authors (ML, JL, XW, XH, QW, SX) independently extracted the data from the included studies, using a modified version of the Cochrane Vascular standard data extraction form. We resolved any disagreements in data extraction and management through discussion and we sought the opinion of a third author (LY or KY), when necessary. We collected the following data:  </p> <p> <ul id="CD010957-list-0008"> <li> <p>study details (e.g. trial name, year, country, authors);</p> </li> <li> <p>methods (e.g. study design, number of participants and study centres, withdrawals and drop‐outs, treatment duration, follow‐up time); </p> </li> <li> <p>participant characteristics (e.g. country, setting, age, sex, inclusion and exclusion criteria, history of VTE, previous major surgery, active cancer, pregnancy, recent period of immobility, hereditary or acquired thrombophilia); </p> </li> <li> <p>interventions (e.g. oral DTIs, oral factor Xa inhibitors);</p> </li> <li> <p>comparisons (e.g. other anticoagulants, i.e. LMWH, UFH, VKAs);</p> </li> <li> <p>outcomes (e.g. recurrent PE, recurrent VTE, clinically overt DVT, all‐cause mortality, major bleeding, health‐related quality of life); </p> </li> <li> <p>funding source;</p> </li> <li> <p>declarations of interest of the study authors.</p> </li> </ul> </p> </section> <section id="CD010957-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Pairs of reviewers (ML, JL, XW, XH) independently assessed the risk of bias using the Cochrane risk of bias tool, as described in section 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010957-bbs2-0081" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). The tool provides a protocol for judgements on sequence generation, allocation methods, blinding, incomplete outcome data, selective outcome reporting, and any other relevant biases. We judged each of these domains as either high, low, or unclear risk of bias according to <a href="./references#CD010957-bbs2-0081" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a> and provided support for each judgement. We presented the conclusions in a <a href="#CD010957-sec-0054">Risk of bias in included studies</a> table. We resolved any disagreements through discussions with a third author (LY or KY). </p> </section> <section id="CD010957-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we used odds ratios (ORs) as the effect measure, with 95% confidence intervals (CIs). For continuous data, we planned to calculate mean differences (MDs) with 95% CIs. If similar outcomes were measured using different scales, we planned to calculate the standardised mean difference (SMD). </p> </section> <section id="CD010957-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in this review was each participant recruited into each included study. </p> </section> <section id="CD010957-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We based the analysis on intention‐to‐treat (ITT) data from the individual clinical trials whenever possible.  We adopted the 'available‐case analysis' if the primary studies did not use ITT analysis. We contacted the study authors for additional information where there were missing or unavailable data. One study author provided missing outcome data when requested (<a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>). In addition, some studies only reported overall data about VTE, with no specific data on PE. We contacted these study authors for detailed information. When we did not get a response within one month, we excluded these studies for the reason "unable to obtain specific outcome data for people with a pulmonary embolism" (see <a href="./references#CD010957-sec-0111" title="">Characteristics of excluded studies</a> table).  </p> </section> <section id="CD010957-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity by checking the study details. We assessed statistical heterogeneity between the trials: by visually examining the forest plots to check for overlapping CIs; with the Chi<sup>2</sup> test for homogeneity with a 10% level of significance; and by using the I<sup>2</sup> statistic to measure the degree of inconsistency between the studies (<a href="./references#CD010957-bbs2-0082" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.">Higgins 2022</a>). We interpreted I² as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010957-bbs2-0067" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.">Deeks 2022</a>): </p> <p> <ul id="CD010957-list-0009"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: may represent considerable heterogeneity.</p> </li> </ul> </p> <p>We planned to investigate the reasons for significant heterogeneity where I<sup>2</sup> was greater than 50% by examining the characteristics of included articles, including participants, interventions, comparisons, outcomes, and study design. </p> </section> <section id="CD010957-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias by funnel plots if a sufficient number of studies (10 or more) were available in the meta‐analyses. In order to investigate any potential selective reporting bias, we compared the full‐text reports of the included studies with the registration information and protocols, and we also searched for eligible studies that had been registered and should have been completed, but were without available published data. </p> </section> <section id="CD010957-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager Web (RevMan Web) to synthesise the data with a meta‐analysis, following the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010957-bbs2-0082" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.">Higgins 2022</a>; <a href="./references#CD010957-bbs2-0106" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). One review author (ML) entered the data into RevMan Web, and the second review author (JL) cross‐checked the data entry. We resolved any discrepancies by consulting the source publication. We used a random‐effects model to synthesise the data, even with a small I², as we expected clinical heterogeneity across studies to exist, due to different oral factor Xa inhibitors (e.g. apixaban, rivaroxaban, edoxaban), different conventional thrombin inhibitors in the control group (e.g. warfarin, dalteparin), different treatment durations (e.g. three, six, and 12 months). If meta‐analysis was not appropriate or possible, we planned to report the results using a narrative synthesis (<a href="./references#CD010957-bbs2-0099" title="McKenzieJE , BrennanSE . Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">McKenzie 2002</a>). </p> </section> <section id="CD010957-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct subgroup analysis for the factors below if there were two or more studies in each subgroup. We planned to analyse the subgroup differences using the Chi<sup>2</sup> test, set at a P value of 0.05. </p> <p> <ul id="CD010957-list-0010"> <li> <p>History of VTE.</p> </li> <li> <p>Age.</p> </li> <li> <p>Active cancer (treatment within the last six months or palliative).</p> </li> <li> <p>Pregnancy.</p> </li> <li> <p>Major surgery requiring general or regional anaesthesia in the previous 12 weeks.</p> </li> <li> <p>Recent period of immobility (bedridden for three or more days in the previous 12 weeks).</p> </li> <li> <p>Thrombophilia (hereditary or acquired).</p> </li> <li> <p>Treatment duration (three months or more than three months).</p> </li> <li> <p>Types of factor Xa inhibitors.</p> </li> </ul> </p> <p>For this update, due to the limited number of included studies, subgroup analyses were only possible for active cancer and the types of factor Xa inhibitors. </p> </section> <section id="CD010957-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the robustness of the results. We intended to exclude studies that we judged to be at high risk of bias (defined as high risk in any domain). We also planned to perform sensitivity analyses with and without studies in ximelagatran, given that this drug is no longer available. However, we found no studies that tested ximelagatran in people with PE. </p> </section> <section id="CD010957-sec-0046"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We developed summary of findings tables, using GRADEpro GDT software, to present the results of this review (<a href="./references#CD010957-bbs2-0077" title="GRADEpro GDT. Version accessed 6 July 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD010957-bbs2-0113" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook2022.">Schünemann 2022a</a>). We created one table each for our two comparisons: 'Oral DTIs versus conventional anticoagulation for the treatment of PE' and 'Oral factor Xa inhibitors versus conventional anticoagulation for the treatment of PE'. We assessed the certainty of the body of evidence for each outcome as high, moderate, low, or very low by considering the risk of bias, inconsistency, indirectness, imprecision, and publication bias according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010957-bbs2-0114" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.">Schünemann 2022b</a>). We assessed the certainty of evidence for the following outcomes: recurrent PE, recurrent VTE, DVT, all‐cause mortality, major bleeding, and health‐related quality of life, as described in the <a href="#CD010957-sec-0028">Types of outcome measures</a> section.  </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010957-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010957-sec-0047"></div> <section id="CD010957-sec-0048"> <h3 class="title">Description of studies</h3> <p>See <a href="#CD010957-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010957-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010957-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <section id="CD010957-sec-0049"> <h4 class="title">Results of the search</h4> <p>For this update, the searches identified 13,412 records, leaving 10,797 records after deduplication. We assessed 10,611 records as not relevant, based on the title and abstract screening. We assessed 186 potentially relevant records by full text. We identified five new included studies (24 reports) and 39 additional reports to already included studies. We excluded 29 studies (90 reports) with reasons, and discarded 20 further reports as not relevant. We identified one study (one report) as awaiting classification, and 10 ongoing studies (12 reports). The previous version of this review included five studies (22 reports). Thus, a total of 10 studies (85 reports) are now included in this review. If an article reported on two studies, we listed the article as an additional publication under each study, which makes both the counts of total reports in included and excluded studies 91. See <a href="#CD010957-fig-0001">Figure 1</a>, <a href="./references#CD010957-sec-0110" title="">Characteristics of included studies</a>, <a href="./references#CD010957-sec-0111" title="">Characteristics of excluded studies</a>, and <a href="./references#CD010957-sec-0113" title="">Characteristics of ongoing studies</a>. </p> </section> <section id="CD010957-sec-0050"> <h4 class="title">Included studies</h4> <p>Ten RCTs involving 13,073 adults met the inclusion criteria for this review (<a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>; <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>). See <a href="./references#CD010957-sec-0110" title="">Characteristics of included studies</a>. </p> <p><a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a> was a double‐blind study in which 5395 participants with a deep vein thrombosis (DVT) or pulmonary embolism (PE) were randomised to receive oral apixaban 10 mg twice daily for the first seven days, followed by 5 mg twice daily for six months or enoxaparin 1 mg/kg of body weight every 12 hours for at least five days and warfarin concomitantly for six months. Participants were followed up for six months. Outcomes included a composite of recurrent symptomatic venous thromboembolism (VTE) (fatal or non‐fatal PE and DVT), mortality related to VTE, major bleeding, and clinically relevant non‐major bleeding. </p> <p><a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a> was a randomised, active‐controlled, open‐label study in which 80 participants with a DVT or PE were randomised to receive oral apixaban 10 mg for seven days as an initial therapy, followed by 5 mg for 23 weeks (n = 40) or continuous infusion of unfractionated heparin (UFH) for at least five days and warfarin concomitantly for 24 weeks (n = 40). Participants were followed up at zero, two, 12, 24, and 28 weeks. Outcomes included major bleeding, clinically relevant non‐major bleeding, all bleeding events, adjudicated recurrent symptomatic VTE (non‐fatal DVT or non‐fatal PE) or VTE‐related death during 24 weeks, and thrombotic burden deterioration at two, 12, and 24 weeks. </p> <p><a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a> was a multinational, randomised, controlled, investigator‐initiated, open‐label, non‐inferiority trial in which 1155 people with a cancer‐associated DVT or PE were randomised to receive oral apixaban 10 mg twice daily for the first seven days, followed by 5 mg twice daily for six months (n = 576) or dalteparin 200 IU/kg of body weight once daily for the first month, followed by 150 IU/kg of body weight daily for six months (n = 579). Participants were followed up at enrolment and at four weeks, then at three, six, and seven months after randomisation. Outcomes included recurrent VTE, recurrent DVT, recurrent PE, fatal PE, major bleeding, major gastrointestinal bleeding, major non‐gastrointestinal bleeding, clinically relevant non‐major bleeding, death from any cause, and event‐free survival. </p> <p><a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a> was an open‐label study in which 4832 participants were randomised to receive oral rivaroxaban 15 mg twice daily for the first three weeks, followed by 20 mg once daily (n = 2419), or enoxaparin 1.0 mg/kg of body weight twice daily and either warfarin or acenocoumarol, started within 48 hours of randomisation (n = 2413). Participants were followed up at three, six, and 12 months. Outcomes included recurrent PE, recurrent DVT, major bleeding, and all‐cause mortality. </p> <p><a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a> was a multinational, prospective, randomised, open‐label, blinded endpoint, non‐inferiority study in which 1046 participants with a cancer‐associated DVT or PE were randomised to receive oral edoxaban at a fixed dose of 60 mg or 30 mg once daily for six to 12 months (n = 522) or dalteparin 200 IU/kg of body weight once daily for 30 days, with a maximum daily dose of 18,000 IU, followed by dalteparin 150 IU/kg of body weight once daily for six to 12 months (n = 524). Participants were followed up on day 31 after randomisation and at three, six, nine, and 12 months. Outcomes included a composite of recurrent VTE, major bleeding, clinically relevant non‐major bleeding, event‐free survival, VTE‐related death, mortality from all causes, recurrent DVT, and recurrent PE. </p> <p><a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a> was a double‐blind study in which 3319 participants were randomised to receive 60 mg oral edoxaban once daily (n = 1650) or dose‐adjusted warfarin therapy and edoxaban‐like placebo (n = 1669). Outcomes were measured monthly for one year. Results were presented for all participants with VTE but specific outcome data for the subset of participants with PE were obtained through communication with the author. </p> <p><a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a> was an open‐label, randomised trial in which 40 participants with a DVT or PE were randomised to receive oral rivaroxaban 15 mg twice daily for a total of three weeks in a double‐blind fashion, followed by open‐label rivaroxaban 15 mg once daily for three, six, or 12 months (n = 33) or UFH for at least five days, overlapping with and followed by an international normalised ratio (INR) (range 1.5 to 2.5) titrated warfarin for three, six, or 12 months (n = 7). Participants were followed up on day 22 and at the end of the three, six, or 12 months' intended treatment period. Outcomes included the occurrence of symptomatic recurrent VTE or asymptomatic deterioration, venous ultrasound and spiral CT, major bleeding, and clinically relevant non‐major bleeding. </p> <p><a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a> was a randomised, open‐label, parallel‐group, multicenter study in which 114 participants with PE were randomised to receive rivaroxaban with food, 15 mg twice daily for 21 days and then 20 mg once daily to study completion for three months (n = 51), or standard of care (any Food and Drug Administration (FDA)‐approved anticoagulant strategy) for three months (n = 63). Participants were followed up at on day 30 and day 90. Outcomes included the total amount of time spent in the hospital, VTE, bleeding events, major bleeding, recurrent VTE, VTE‐related death, satisfaction with anticlot treatment, total costs of care, and clinically relevant non‐major bleeding. </p> <p><a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> was a phase III, non‐inferiority, double‐blind, double‐dummy trial in which people with VTE (n = 2539) were given 150 mg dabigatran twice daily or warfarin. In addition, initial treatment with an approved parenteral anticoagulant (UFH administered intravenously or low molecular weight heparin (LMWH) administered subcutaneously) was started before participants were randomised. Treatment was for a period of six months and included sham monitoring of INR and sham titration of warfarin in the control group. To gain regulatory approval, the study was repeated with an identical design (<a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>). <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> only reported outcome data of VTE, not separate data for PE, so we took data from a pooled analysis published in an additional report (<a href="./references#CD010957-bbs2-0076" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21.">Goldhaber 2016</a>).  </p> </section> <section id="CD010957-sec-0051"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD010957-sec-0111" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 29 studies (<a href="./references#CD010957-bbs2-0011" title="McBaneRD , McBaneLR , LoprinziCL , AshraniA , Perez-BoteroJ , Ferre Ra Leon, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. Thrombosis and Haemostasis2017;117(10):1952-61. McBaneRD , WysokinskiWE , Le-RademacherJG , ZemlaT , AshraniA , TafurA , et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. Journal of Thrombosis and Haemostasis2020;18(2):411-21. NCT02585713. Apixaban or dalteparin in reducing blood clots in patients with cancer related venous thromboembolism. clinicaltrials.gov/ct2/show/NCT02585713 (first received 20 November 2015). ">ADAM VTE trial 2020</a>; <a href="./references#CD010957-bbs2-0012" title="AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for extended treatment of venous thromboembolism. New England Journal of Medicine2013;368(8):699-708. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonMR , et al. Two doses of apixaban for the extended treatment of venous thromboembolism. Blood2012;120(21):LBA-1. LiuX , ThompsonJ , PhatakH , MardekianJ , PorcariAR , JohnsonMR . Apixaban reduces hospitalization in patients with venous thromboembolism: an analysis of the AMPLIFY-EXT trial. Blood2013;122(21):[no pagination]. ">AMPLIFY Extended 2013</a>; <a href="./references#CD010957-bbs2-0013" title="BorsiSH , RajiH , Dargahi MalamirM , NokhostinF , KargaranA . Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism: a randomized clinial trial. Tehran University Medical Journal Sciences Journals2021;79(4):281-9. ">Borsi 2021</a>; <a href="./references#CD010957-bbs2-0014" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. BotticelliIWC , BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6(8):1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis-The Botticelli Investigators. In: XXIst Congress of the International Society on Thrombosis and Haemostasis. Geneva, 2007. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005 (first received November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010957-bbs2-0015" title="NCT02746185. Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). clinicaltrials.gov/ct2/show/NCT02746185 (first received 21 April 2016). PlanquetteB , BertolettiL , Charles-NelsonA , LaporteS , GrangeC , MahéI , et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest2022;161(3):781-90. ">CASTA DIVA Trial 2022</a>; <a href="./references#CD010957-bbs2-0016" title="CastellucciLA , HoggK , ChiangP , WuCM , TemplierGL , GalGL , et al. Comparison of bleeding risk between rivaroxaban and apixaban: a pilot feasibility study. Blood2017;130 (Suppl 1):1108. ">COBRRA pilot feasibility study 2017</a>; <a href="./references#CD010957-bbs2-0017" title="EUCTR2015-001478-16-DE. The role of rivaroxaban in the treatment of tumor patients with thrombosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2015-001478-16-DE (first received 9 September 2015). NCT02583191. Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. clinicaltrials.gov/ct2/show/NCT02583191 (first received 22 October 2015). RiessH , SinnM , KreherS . CONKO-011: Evaluation of patient satisfaction with the treatment of acute venous thromboembolism with rivaroxaban or low molecular weight heparin in cancer patients. A randomized phase III study [CONKO-011: Evaluation der Patientenzufriedenheit bei der Behandlung akuter venöser Thromboembolien mit Rivaroxaban oder niedermolekularem Heparin bei Krebspatienten]. Deutsche Medizinische Wochenschrift2015;140 (Suppl 1):S22-3. RiessH , SinnM , LohneisA , HellmannM , StrieflerJ , SüdhoffT , et al. Improved patient-reported treatment satisfaction with rivaroxaban as compared to low molecular weight heparins for cancer patients with acute venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2021;5 (Suppl 2):[no pagination]. SinnM , JuhlingA , HellmannM , OmarM , SudhoffT , StahlM , et al. Patient-reported treatment satisfaction with rivaroxaban in cancer patients with acute venous thromboembolism - Results from the CONKO-011 trial. Oncology Research and Treatment2021;44 (Suppl 2):276-7. ">CONKO‐011 2015</a>; <a href="./references#CD010957-bbs2-0018" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients Legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). SoaresR , MatieloMF , NetoF , NogueiraMP , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. ">de Athayde Soares 2019</a>; <a href="./references#CD010957-bbs2-0019" title="AlbisettiM , BissB , BomgaarsL , BrandãoLR , BrueckmannM , ChalmersE , et al. Design and rationale for the DIVERSITY study: an open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2018;2(2):347-56. AlbisettiM , BrandãoL , BomgaarsL , ChalmersE , LucianiM , MitchellL , et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients - results of the DIVERSITY trial. Research and Practice in Thrombosis and Haemostasis2019;3:139-40. AlbisettiM , TartakovskyI , HaltonJ , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran in the treatment and secondary prevention of venous thromboembolism in children with central line or implantable device–related thrombosis. Research and Practice in Thrombosis and Haemostasis2021;5 (Suppl 2):[no pagination]. BrandãoL , TartakovskyI , HaltonJ , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran in the treatment and secondary prevention of venous thromboembolism in children with cerebral venous and sinus thrombosis. Research and Practice in Thrombosis and Haemostasis2021;5 (Suppl 2):[no pagination]. EUCTR2013-002114-12. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with VTE. trialsearch.who.int/?TrialID=EUCTR2013%E2%80%90002114%E2%80%9012%E2%80%90Outside%E2%80%90EU/EEA (first received 18 Feburary 2014). HaltonJ , BrandoLR , LucianiM , BomgaarsL , Woods-SwaffordW , MitchellLG , et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematology2021;8(1):E22-E33. HaltonJ , BrandãoL , LucianiM , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients aged from birth to &lt; 2 years: results of the DIVERSITY Trial. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):35. NCT01895777. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT01895777 (first received 11 July 2013). ">DIVERSITY trial 2021</a>; <a href="./references#CD010957-bbs2-0020" title="PrandoniP , LensingAW , PrinsMH , GebelM , PapAF , HomeringM , et al. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research2018;168:121-9. WeitzJI , LensingAW , PrinsMH , BauersachsR , Beyer-WestendorfJ , BounameauxH , et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New England Journal of Medicine2017;376(13):1211-22. ">EINSTEIN‐CHOICE trial 2017</a>; <a href="./references#CD010957-bbs2-0022" title="BullerH , DariusH . EINSTEIN DVT: Oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/congresses/esc-2010/congress-reports/Pages/708-4-EINSTEIN-DVT.aspx#.UvNXl03itMs2010. BullerHR , AgnelliG . Once-or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Pt 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor XA inhibitor bay59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772 (first received December 2004). ">Einstein‐DVT Dose 2008</a>; <a href="./references#CD010957-bbs2-0021" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11:30-1. BistervelsIM , BavaliaR , GebelM , LensingAW , MiddeldorpS , PrinsMH , et al. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Journal of Thrombosis and Haemostasis2022;20(6):1376-84. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCAJ , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002171-16 (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004495-13 (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22(5):S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - the EINSTEIN DVT study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrandoniP . Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. Thrombosis Research2014;134(2):227-33. ">Einstein DVT 2013</a>; <a href="./references#CD010957-bbs2-0023" title="NCT00439725. Once - daily oral direct factor Xa inhibitor rivaroxaban In the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. clinicaltrials.gov/ct2/show/NCT00439725 (first received 26 February 2007). ">EINSTEIN Extension 2007</a>; <a href="./references#CD010957-bbs2-0024" title="LensingAW , MaleC , YoungG , KubitzaD , KenetG , PatriciaMM , et al. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thrombosis Journal2018;16:34. MaleC , LensingAW , PalumboJS , KumarR , NurmeevI , HegeK , et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology2020;7(1):e18-e27. NCT02234843. EINSTEIN junior: oral rivaroxaban in children with venous thrombosis (EINSTEIN Jr). clinicaltrials.gov/ct2/show/NCT02234843 (first received 13 November 2014). ThomK , LensingAW , NurmeevI , BajolleF , BonnetD , KenetG , et al. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances2020;4(19):4632-9. ">EINSTEIN‐Jr Trial 2020</a>; <a href="./references#CD010957-bbs2-0025" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010957-bbs2-0026" title="NCT02066662. Rivaroxaban compared to vitamin K antagonist upon development of cardiovascular calcification. clinicaltrials.gov/ct2/show/NCT02066662 (first received 19 February 2014). StöhrR , DirrichsT , KneizehK , ReinartzS , FrankD , BrachmannJ , et al. Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism. Clinical Cardiology2022;45(4):352-8. ">IRIVASC‐Trial 2022</a>; <a href="./references#CD010957-bbs2-0027" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010957-bbs2-0028" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116(2):180-7. NCT00839163. Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic proximal deep vein thrombosis (ODIXa-DVT). clinicaltrials.gov/ct2/show/NCT00839163 (first received 9 Febuary 2009). ">ODIXa‐DVT 2007</a>; <a href="./references#CD010957-bbs2-0029" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual Disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2018</a>; <a href="./references#CD010957-bbs2-0030" title="NCT01662908. A randomized, open-label, parallel-group, multi-center study for the evaluation of efficacy and safety of edoxaban monotherapy versus low molecular weight (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis (eTRIS). clinicaltrials.gov/ct2/show/NCT01662908 (first received 13 August 2012). PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (eTRIS). Circulation2014;130(2):A12074. ">Piazza 2014</a>; <a href="./references#CD010957-bbs2-0031" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute Iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral Venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. ">PRAIS trial 2019</a>; <a href="./references#CD010957-bbs2-0032" title="KimJH , YooC , SeoS , JeongJH , RyooBY , KimKP , et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers (Basel)2022;14(3):559. NCT03139487. A randomized phase II open label study to compare the safety and iefficacy of subcutaneous dalteparin versus direct oral anticoagulants for cancer-associated venous thromboembolism. clinicaltrials.gov/ct2/show/NCT03139487 (first received 4 May 2017). ">PRIORITY 2022</a>; <a href="./references#CD010957-bbs2-0033" title="LiemTK , DeLougheryTG . Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE. Evidence Based Medicine2014;19(1):29. SchulmanS , KearonC , KakkarAK , SchellongS , ErikssonH , BaanstraD , et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine2013;368(8):709-18. ">REMEDY 2013</a>; <a href="./references#CD010957-bbs2-0034" title="SchulmanS , BaanstraD , ErikssonH , GoldhaberS , KakkarA , KearonC , et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9 (Suppl 2):22. SchulmanS , BaanstraD , ErikssonH , GoldhaberSZ , KakkarA , KearonC , et al. Benefit of extended maintenance therapy for venous thromboembolism with dabigatran etexilate is maintained over 1 year of post-treatment follow-up. Blood (ASH Annual Meeting Abstracts)2012;120 (21):Abstract 332. SchulmanS , KearonC , KakkarAK , SchellongS , ErikssonH , BaanstraD , et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine2013;368(8):709-18. ">RE‐SONATE 2013</a>; <a href="./references#CD010957-bbs2-0035" title="EUCTR2012-005589-37-GB. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012-005589-37-GB (first received 8 February 2013). YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology2014;32(32):Suppl 1. YoungA , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). Journal of Clinical Oncology2018;36(20):2017-23. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130 (Suppl 1):[no pagination]. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140(Suppl 1):S172-3. ">SELECT‐D 2018</a>; <a href="./references#CD010957-bbs2-0036" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiology and Vascular Surgery2017;23(2):82. ">Sukovatykh 2017</a>; <a href="./references#CD010957-bbs2-0037" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1 (Suppl 1):[no pagination]. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125 (Suppl 1):66. ">THRIVE 2005</a>; <a href="./references#CD010957-bbs2-0038" title="ErikssonH , WahlanderK , GustafssonD , WelinLT , FrisonL , SchulmanS , et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis2003;1(1):41-7. ">THRIVE I 2003</a>; <a href="./references#CD010957-bbs2-0039" title="ErikssonH , LundstromT , WahlanderK , ClasonSB , SchulmanS . Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thrombosis and Haemostasis2005;94(3):522-7. ErikssonH , WahlanderK , LundstromT , Billing ClasonS , SchulmanS . Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood2002;100:81a. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. SchulmanS , WahlanderK , LundstromT , ClasonSB , ErikssonH . Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New England Journal of Medicine2003;349(18):1713-21. ">THRIVE III 2003</a>). We excluded 11 studies as participants had DVT only (<a href="./references#CD010957-bbs2-0014" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. BotticelliIWC , BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6(8):1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis-The Botticelli Investigators. In: XXIst Congress of the International Society on Thrombosis and Haemostasis. Geneva, 2007. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005 (first received November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010957-bbs2-0018" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients Legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). SoaresR , MatieloMF , NetoF , NogueiraMP , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. ">de Athayde Soares 2019</a>; <a href="./references#CD010957-bbs2-0022" title="BullerH , DariusH . EINSTEIN DVT: Oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/congresses/esc-2010/congress-reports/Pages/708-4-EINSTEIN-DVT.aspx#.UvNXl03itMs2010. BullerHR , AgnelliG . Once-or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Pt 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor XA inhibitor bay59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772 (first received December 2004). ">Einstein‐DVT Dose 2008</a>; <a href="./references#CD010957-bbs2-0021" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11:30-1. BistervelsIM , BavaliaR , GebelM , LensingAW , MiddeldorpS , PrinsMH , et al. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Journal of Thrombosis and Haemostasis2022;20(6):1376-84. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCAJ , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002171-16 (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004495-13 (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22(5):S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - the EINSTEIN DVT study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrandoniP . Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. Thrombosis Research2014;134(2):227-33. ">Einstein DVT 2013</a>; <a href="./references#CD010957-bbs2-0025" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010957-bbs2-0027" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010957-bbs2-0028" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116(2):180-7. NCT00839163. Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic proximal deep vein thrombosis (ODIXa-DVT). clinicaltrials.gov/ct2/show/NCT00839163 (first received 9 Febuary 2009). ">ODIXa‐DVT 2007</a>; <a href="./references#CD010957-bbs2-0029" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual Disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2018</a>; <a href="./references#CD010957-bbs2-0030" title="NCT01662908. A randomized, open-label, parallel-group, multi-center study for the evaluation of efficacy and safety of edoxaban monotherapy versus low molecular weight (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis (eTRIS). clinicaltrials.gov/ct2/show/NCT01662908 (first received 13 August 2012). PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (eTRIS). Circulation2014;130(2):A12074. ">Piazza 2014</a>; <a href="./references#CD010957-bbs2-0031" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute Iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral Venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. ">PRAIS trial 2019</a>; <a href="./references#CD010957-bbs2-0036" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiology and Vascular Surgery2017;23(2):82. ">Sukovatykh 2017</a>). We excluded 11 studies as although all participants had a VTE, specific data on the subgroup with PE were not published (<a href="./references#CD010957-bbs2-0011" title="McBaneRD , McBaneLR , LoprinziCL , AshraniA , Perez-BoteroJ , Ferre Ra Leon, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. Thrombosis and Haemostasis2017;117(10):1952-61. McBaneRD , WysokinskiWE , Le-RademacherJG , ZemlaT , AshraniA , TafurA , et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. Journal of Thrombosis and Haemostasis2020;18(2):411-21. NCT02585713. Apixaban or dalteparin in reducing blood clots in patients with cancer related venous thromboembolism. clinicaltrials.gov/ct2/show/NCT02585713 (first received 20 November 2015). ">ADAM VTE trial 2020</a>; <a href="./references#CD010957-bbs2-0013" title="BorsiSH , RajiH , Dargahi MalamirM , NokhostinF , KargaranA . Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism: a randomized clinial trial. Tehran University Medical Journal Sciences Journals2021;79(4):281-9. ">Borsi 2021</a>; <a href="./references#CD010957-bbs2-0015" title="NCT02746185. Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). clinicaltrials.gov/ct2/show/NCT02746185 (first received 21 April 2016). PlanquetteB , BertolettiL , Charles-NelsonA , LaporteS , GrangeC , MahéI , et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest2022;161(3):781-90. ">CASTA DIVA Trial 2022</a>; <a href="./references#CD010957-bbs2-0016" title="CastellucciLA , HoggK , ChiangP , WuCM , TemplierGL , GalGL , et al. Comparison of bleeding risk between rivaroxaban and apixaban: a pilot feasibility study. Blood2017;130 (Suppl 1):1108. ">COBRRA pilot feasibility study 2017</a>; <a href="./references#CD010957-bbs2-0017" title="EUCTR2015-001478-16-DE. The role of rivaroxaban in the treatment of tumor patients with thrombosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2015-001478-16-DE (first received 9 September 2015). NCT02583191. Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. clinicaltrials.gov/ct2/show/NCT02583191 (first received 22 October 2015). RiessH , SinnM , KreherS . CONKO-011: Evaluation of patient satisfaction with the treatment of acute venous thromboembolism with rivaroxaban or low molecular weight heparin in cancer patients. A randomized phase III study [CONKO-011: Evaluation der Patientenzufriedenheit bei der Behandlung akuter venöser Thromboembolien mit Rivaroxaban oder niedermolekularem Heparin bei Krebspatienten]. Deutsche Medizinische Wochenschrift2015;140 (Suppl 1):S22-3. RiessH , SinnM , LohneisA , HellmannM , StrieflerJ , SüdhoffT , et al. Improved patient-reported treatment satisfaction with rivaroxaban as compared to low molecular weight heparins for cancer patients with acute venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2021;5 (Suppl 2):[no pagination]. SinnM , JuhlingA , HellmannM , OmarM , SudhoffT , StahlM , et al. Patient-reported treatment satisfaction with rivaroxaban in cancer patients with acute venous thromboembolism - Results from the CONKO-011 trial. Oncology Research and Treatment2021;44 (Suppl 2):276-7. ">CONKO‐011 2015</a>; <a href="./references#CD010957-bbs2-0019" title="AlbisettiM , BissB , BomgaarsL , BrandãoLR , BrueckmannM , ChalmersE , et al. Design and rationale for the DIVERSITY study: an open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2018;2(2):347-56. AlbisettiM , BrandãoL , BomgaarsL , ChalmersE , LucianiM , MitchellL , et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients - results of the DIVERSITY trial. Research and Practice in Thrombosis and Haemostasis2019;3:139-40. AlbisettiM , TartakovskyI , HaltonJ , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran in the treatment and secondary prevention of venous thromboembolism in children with central line or implantable device–related thrombosis. Research and Practice in Thrombosis and Haemostasis2021;5 (Suppl 2):[no pagination]. BrandãoL , TartakovskyI , HaltonJ , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran in the treatment and secondary prevention of venous thromboembolism in children with cerebral venous and sinus thrombosis. Research and Practice in Thrombosis and Haemostasis2021;5 (Suppl 2):[no pagination]. EUCTR2013-002114-12. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with VTE. trialsearch.who.int/?TrialID=EUCTR2013%E2%80%90002114%E2%80%9012%E2%80%90Outside%E2%80%90EU/EEA (first received 18 Feburary 2014). HaltonJ , BrandoLR , LucianiM , BomgaarsL , Woods-SwaffordW , MitchellLG , et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematology2021;8(1):E22-E33. HaltonJ , BrandãoL , LucianiM , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients aged from birth to &lt; 2 years: results of the DIVERSITY Trial. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):35. NCT01895777. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT01895777 (first received 11 July 2013). ">DIVERSITY trial 2021</a>; <a href="./references#CD010957-bbs2-0024" title="LensingAW , MaleC , YoungG , KubitzaD , KenetG , PatriciaMM , et al. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thrombosis Journal2018;16:34. MaleC , LensingAW , PalumboJS , KumarR , NurmeevI , HegeK , et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology2020;7(1):e18-e27. NCT02234843. EINSTEIN junior: oral rivaroxaban in children with venous thrombosis (EINSTEIN Jr). clinicaltrials.gov/ct2/show/NCT02234843 (first received 13 November 2014). ThomK , LensingAW , NurmeevI , BajolleF , BonnetD , KenetG , et al. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances2020;4(19):4632-9. ">EINSTEIN‐Jr Trial 2020</a>; <a href="./references#CD010957-bbs2-0026" title="NCT02066662. Rivaroxaban compared to vitamin K antagonist upon development of cardiovascular calcification. clinicaltrials.gov/ct2/show/NCT02066662 (first received 19 February 2014). StöhrR , DirrichsT , KneizehK , ReinartzS , FrankD , BrachmannJ , et al. Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism. Clinical Cardiology2022;45(4):352-8. ">IRIVASC‐Trial 2022</a>; <a href="./references#CD010957-bbs2-0032" title="KimJH , YooC , SeoS , JeongJH , RyooBY , KimKP , et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers (Basel)2022;14(3):559. NCT03139487. A randomized phase II open label study to compare the safety and iefficacy of subcutaneous dalteparin versus direct oral anticoagulants for cancer-associated venous thromboembolism. clinicaltrials.gov/ct2/show/NCT03139487 (first received 4 May 2017). ">PRIORITY 2022</a>; <a href="./references#CD010957-bbs2-0035" title="EUCTR2012-005589-37-GB. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012-005589-37-GB (first received 8 February 2013). YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology2014;32(32):Suppl 1. YoungA , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). Journal of Clinical Oncology2018;36(20):2017-23. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130 (Suppl 1):[no pagination]. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140(Suppl 1):S172-3. ">SELECT‐D 2018</a>; <a href="./references#CD010957-bbs2-0037" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1 (Suppl 1):[no pagination]. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125 (Suppl 1):66. ">THRIVE 2005</a>). We made attempts to contact the authors for these data but were unsuccessful. We excluded three studies as they were extended studies testing the effectiveness of DOACs as prophylaxis rather than the treatment of PE (<a href="./references#CD010957-bbs2-0012" title="AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for extended treatment of venous thromboembolism. New England Journal of Medicine2013;368(8):699-708. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonMR , et al. Two doses of apixaban for the extended treatment of venous thromboembolism. Blood2012;120(21):LBA-1. LiuX , ThompsonJ , PhatakH , MardekianJ , PorcariAR , JohnsonMR . Apixaban reduces hospitalization in patients with venous thromboembolism: an analysis of the AMPLIFY-EXT trial. Blood2013;122(21):[no pagination]. ">AMPLIFY Extended 2013</a>; <a href="./references#CD010957-bbs2-0023" title="NCT00439725. Once - daily oral direct factor Xa inhibitor rivaroxaban In the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. clinicaltrials.gov/ct2/show/NCT00439725 (first received 26 February 2007). ">EINSTEIN Extension 2007</a>; <a href="./references#CD010957-bbs2-0033" title="LiemTK , DeLougheryTG . Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE. Evidence Based Medicine2014;19(1):29. SchulmanS , KearonC , KakkarAK , SchellongS , ErikssonH , BaanstraD , et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine2013;368(8):709-18. ">REMEDY 2013</a>). We excluded the <a href="./references#CD010957-bbs2-0038" title="ErikssonH , WahlanderK , GustafssonD , WelinLT , FrisonL , SchulmanS , et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis2003;1(1):41-7. ">THRIVE I 2003</a> study as treatment was for less than three months, and the <a href="./references#CD010957-bbs2-0039" title="ErikssonH , LundstromT , WahlanderK , ClasonSB , SchulmanS . Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thrombosis and Haemostasis2005;94(3):522-7. ErikssonH , WahlanderK , LundstromT , Billing ClasonS , SchulmanS . Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood2002;100:81a. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. SchulmanS , WahlanderK , LundstromT , ClasonSB , ErikssonH . Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New England Journal of Medicine2003;349(18):1713-21. ">THRIVE III 2003</a> study as the control arm was a placebo. We excluded <a href="./references#CD010957-bbs2-0020" title="PrandoniP , LensingAW , PrinsMH , GebelM , PapAF , HomeringM , et al. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research2018;168:121-9. WeitzJI , LensingAW , PrinsMH , BauersachsR , Beyer-WestendorfJ , BounameauxH , et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New England Journal of Medicine2017;376(13):1211-22. ">EINSTEIN‐CHOICE trial 2017</a> as the control arm was aspirin. Finally, we excluded the <a href="./references#CD010957-bbs2-0033" title="LiemTK , DeLougheryTG . Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE. Evidence Based Medicine2014;19(1):29. SchulmanS , KearonC , KakkarAK , SchellongS , ErikssonH , BaanstraD , et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine2013;368(8):709-18. ">REMEDY 2013</a> study from this review as participants were already included in the <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> studies.  </p> </section> <section id="CD010957-sec-0052"> <h4 class="title">Studies awaiting classification</h4> <p>One trial record is awaiting classification as there are currently insufficient details to assess its eligibility for inclusion (<a href="./references#CD010957-bbs2-0040" title="NCT01780987. A study to evaluate safety and efficacy of apixaban in Japanese acute deep vein thrombosis (DVT) and pulmonary embolism (PE) patients. clinicaltrials.gov/show/NCT01780987 (first received 30 July 2022). ">NCT01780987</a>). </p> </section> <section id="CD010957-sec-0053"> <h4 class="title">Ongoing studies</h4> <p>Ten trials are ongoing and there are currently no suitable data available for including in this review (<a href="./references#CD010957-bbs2-0041" title="EudraCT 2014-002606-20. A randomized, open-label, active controlled, safety and descriptive efficacy study in pediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event. clinicaltrialsregister.eu/ctr-search/trial/2014-002606-20/3rd (first received 8 June 2015). ">EudraCT 2014‐002606‐20</a>; <a href="./references#CD010957-bbs2-0042" title="NCT02464969. Apixaban for the acute treatment of venous thromboembolism in children. clinicaltrials.gov/ct2/show/NCT02464969 (first received 8 June 2015). ">NCT02464969</a>; <a href="./references#CD010957-bbs2-0043" title="NCT02664155. Venous thromboembolism in renally impaired patients and direct oral anticoagulants. clinicaltrials.gov/ct2/show/NCT02664155 (first received 26 January 2016). ">NCT02664155</a>; <a href="./references#CD010957-bbs2-0044" title="NCT02744092. Direct oral anticoagulants (DOACs) versus LMWH +/- warfarin for VTE in cancer. clinicaltrials.gov/ct2/show/NCT02744092 (first received 20 April 2016). SchragD , UnoH , RosovskyRP , RutherfordCJ , SanfilippoKM , VillanoJL , et al. The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: the CANVAS pragmatic randomized trial. Journal of Clinical Oncology2021;39(Suppl 15):12020. ">NCT02744092</a>; <a href="./references#CD010957-bbs2-0045" title="NCT02798471. Hokusai study in pediatric patients with confirmed venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02798471 (first received 14 June 2016). Van OmmenCH , AlbisettiM , ChanAK , EsteppJ , JaffrayJ , KenetG , et al. The Edoxaban Hokusai VTE PEDIATRICS Study: an open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease. Research and Practice in Thrombosis and Haemostasis2020;4(5):886-92. ">NCT02798471</a>; <a href="./references#CD010957-bbs2-0046" title="NCT03129555. The Danish non-vitamin K antagonist oral anticoagulation study in patients with venous thromboembolism (DANNOAC-VTE). clinicaltrials.gov/ct2/show/NCT03129555 (first received 26 April 2017). ">NCT03129555</a>; <a href="./references#CD010957-bbs2-0047" title="NCT03266783. Comparison of bleeding risk between rivaroxaban and apixaban for the treatment of acute venous thromboembolism (COBRRA). clinicaltrials.gov/ct2/show/NCT03266783 (first received 30 August 2017). ">NCT03266783</a>; <a href="./references#CD010957-bbs2-0048" title="NCT05171049. A study comparing abelacimab to apixaban in the treatment of cancer-associated VTE (ASTER). clinicaltrials.gov/ct2/show/NCT05171049 (first received 28 December 2021). ">NCT05171049</a>; <a href="./references#CD010957-bbs2-0049" title="PettitKL , KlineJA . High treatment failure rates with rivaroxaban and apixaban in a randomized controlled trial of young women with venous thromboembolism. Academic Emergency Medicine2018;25(Suppl 1):S263-4. ">Pettit 2018</a>; <a href="./references#CD010957-bbs2-0050" title="UMIN000020069. Comparison of efficacy and safety between warfarin, rivaroxaban and edoxaban in patients with acute pulmonary embolism in showa university. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023184 (first received 10 December 2015). ">UMIN000020069</a>). See <a href="./references#CD010957-sec-0113" title="">Characteristics of ongoing studies</a>.  </p> </section> </section> <section id="CD010957-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD010957-fig-0002">Figure 2</a> and <a href="#CD010957-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010957-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010957-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010957-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010957-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010957-sec-0055"> <h4 class="title">Allocation</h4> <p>All 10 included studies stated that they used a computerised system to generate the random sequence, so we deemed the risk of selection bias relating to random sequence generation to be low. All 10 included studies reported that treatment allocation was concealed with the use of a computerised system, so we judged them to be at low risk of selection bias for allocation concealment (<a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>; <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>). </p> </section> <section id="CD010957-sec-0056"> <h4 class="title">Blinding</h4> <p>The <a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>, <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>, <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>, <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>, <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>, and <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a> studies were open‐label: blinding of participants and personnel was not conducted. However, we judged that the lack of blinding in the control group was unlikely to have affected the outcome, and we thus judged these studies to have a low risk of performance bias. The <a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>, <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>, <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>, and <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a> studies were double‐blind and therefore we judged them to be at low risk of performance bias. </p> <p>All studies blinded outcome assessors to treatment; therefore, we judged them to be at low risk of detection bias.  </p> </section> <section id="CD010957-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>Nine studies sufficiently reported that fewer than 20% of participants dropped out or withdrew, and these numbers were balanced across treatment groups. Therefore, we judged them to be at low risk of attrition bias (<a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>; <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>). The <a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a> study inappropriately excluded a number of randomised participants from the ITT analysis. Furthermore, a large number of participants within each treatment group were classified as discontinuing the study for "other reasons" with no explanations given, and we therefore deemed the risk of attrition bias to be unclear. </p> </section> <section id="CD010957-sec-0058"> <h4 class="title">Selective reporting</h4> <p>Eight studies clearly pre‐specified the study outcomes and data on the expected outcomes were presented (<a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>; <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>); we judged these studies to be at low risk of reporting bias. The <a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a> study pre‐defined minor bleeding as a secondary outcome but data were not reported in the paper, and therefore we deemed the risk of reporting bias in this study to be high. The <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a> study pre‐defined quality of life as a secondary outcome in the protocol but the data on this outcome were not reported in the paper; therefore we deemed the risk of reporting bias to be high. </p> </section> <section id="CD010957-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find any methodological issues that might directly lead to a risk of bias; therefore, we deemed the risk of other bias to be low in all 10 included studies.  </p> </section> </section> <section id="CD010957-sec-0060"> <h3 class="title" id="CD010957-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD010957-tbl-0001"><b>Summary of findings 1</b> Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation for the treatment of pulmonary embolism</a>; <a href="./full#CD010957-tbl-0002"><b>Summary of findings 2</b> Oral factor Xa inhibitors versus conventional anticoagulation for the treatment of pulmonary embolism</a> </p> <p>We identified two studies that compared an oral DTI versus conventional anticoagulation with warfarin (<a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>), and eight studies that compared an oral factor Xa inhibitor versus conventional anticoagulation with warfarin or dalteparin (<a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>). We did not find any studies comparing one DTI with another DTI, one factor Xa inhibitor with another factor Xa inhibitor, or an oral DTI with a factor Xa inhibitor. We used a random‐effects model for all analyses due to clinical heterogeneity across studies (different oral factor Xa inhibitors, different conventional thrombin inhibitors in the control group, and different treatment durations). </p> <section id="CD010957-sec-0061"> <h4 class="title">Oral direct thrombin inhibitor versus conventional anticoagulation</h4> <p>In the meta‐analysis of oral DTIs versus conventional anticoagulation, we used data from <a href="./references#CD010957-bbs2-0076" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21.">Goldhaber 2016</a>, which reported combined data from the <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> studies. This is reflected in the data analysis tables and <a href="./full#CD010957-tbl-0001">summary of findings Table 1</a> by showing only one study for this comparison. </p> <section id="CD010957-sec-0062"> <h5 class="title">Recurrent pulmonary embolism</h5> <p>Two studies with a combined total of 1602 participants measured recurrent pulmonary embolism (PE) (<a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>). There was no clear difference in the rate of recurrent PE between participants treated with dabigatran (16 events/795 participants) and those treated with conventional anticoagulation (16 events/807 participants) leading to an odds ratio (OR) of 1.02 (95% confidence interval (CI) 0.50 to 2.04; 2 studies, 1602 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD010957-sec-0063"> <h5 class="title">Recurrent venous thromboembolism</h5> <p>Two studies with a combined total of 1602 participants measured recurrent venous thromboembolism (VTE) (<a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>). There was no clear difference in the rate of recurrent VTE between participants treated with dabigatran (23 events/795 participants) and those treated with conventional anticoagulation (25 events/807 participants) leading to an OR of 0.93 (95% CI 0.52 to 1.66; 2 studies, 1602 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD010957-sec-0064"> <h5 class="title">Deep vein thrombosis</h5> <p>Two studies with a combined total of 1602 participants measured deep vein thrombosis (DVT) (<a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>). There was no clear difference in the rate of DVT between participants treated with dabigatran (7 events/795 participants) and those treated with conventional anticoagulation (9 events/807 participants) leading to an OR of 0.79 (95% CI 0.29 to 2.13; 2 studies, 1602 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD010957-sec-0065"> <h5 class="title">All‐cause mortality</h5> <p>Neither study presented results on all‐cause mortality for the specific group of participants with PE. </p> </section> <section id="CD010957-sec-0066"> <h5 class="title">Adverse effects of treatment</h5> <p>Both <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> measured major bleeding (as defined by the International Society on Thrombosis and Haemostasis (ISTH); <a href="./references#CD010957-bbs2-0111" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>). There was no clear difference in the rate of major bleeding between participants treated with oral DTIs (4 events/759 participants) and those treated with conventional anticoagulation (8 events/768 participants) leading to an OR of 0.50 (95% CI 0.15 to 1.68; 2 studies, 1602 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD010957-sec-0067"> <h5 class="title">Health‐related quality of life</h5> <p>Health‐related quality of life was not a reported outcome in either <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> or <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>. </p> </section> </section> <section id="CD010957-sec-0068"> <h4 class="title">Oral factor Xa inhibitor versus conventional anticoagulation</h4> <p>See <a href="./full#CD010957-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD010957-sec-0069"> <h5 class="title">Recurrent pulmonary embolism</h5> <p>Data on recurrent PE was available in three studies with 8186 participants (<a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>). The duration of treatment in all three studies was longer than three months. Meta‐analysis showed no clear difference in the rate of recurrent PE between participants treated with oral factor Xa inhibitors (67 events/4087 participants) and those treated with conventional anticoagulation (73 events/4099 participants), leading to an OR of 0.92 (95% CI 0.66 to 1.29; I<sup>2</sup> = 0; 3 studies, 8186 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0008" title="">Analysis 2.1</a>).  </p> </section> <section id="CD010957-sec-0070"> <h5 class="title">Recurrent venous thromboembolism</h5> <p>We included eight studies with a combined total of 11,416 participants in a meta‐analysis (<a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>). The treatment duration of <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a> was three months, and the events in both groups were 0, so it was not estimated in the meta‐analysis. The treatment duration of the other seven studies was longer than three months. Meta‐analysis showed no clear difference in the rate of recurrent VTE between participants treated with oral factor Xa inhibitors (150 events/5698 participants) and those treated with conventional anticoagulation (183 events/5718 participants), leading to an OR of 0.83 (95% CI 0.66 to 1.03; I<sup>2</sup> = 0%; 8 studies, 11,416 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0009" title="">Analysis 2.2</a>).  </p> </section> <section id="CD010957-sec-0071"> <h5 class="title">Deep vein thrombosis</h5> <p>We included two studies with a combined total of 8151 participants in a meta‐analysis (<a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>). There was no clear difference in the rate of recurrent DVT between participants treated with oral factor Xa inhibitors (30 events/4069 participants) and those treated with conventional anticoagulation (39 events/4082 participants), leading to an OR of 0.77 (95% CI 0.48 to 1.25; I<sup>2</sup> = 0; 2 studies, 8151 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0010" title="">Analysis 2.3</a>). The <a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a> study did not present DVT data for the subgroup of participants with a PE and therefore we did not include it in this meta‐analysis. </p> </section> <section id="CD010957-sec-0072"> <h5 class="title">All‐cause mortality</h5> <p>Three studies measured all‐cause mortality (<a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>). In the <a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a> and <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a> studies, the events in both groups were 0, so they were not estimated in the meta‐analysis. There was no clear difference in the rate of all‐cause mortality between participants treated with the oral factor Xa inhibitor rivaroxaban (2.40%; 58 events/2412 participants) and those treated with conventional anticoagulation (50 events/2405 participants), leading to an OR of 1.16 (95% CI 0.79 to 1.70; 1 study, 4817 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0011" title="">Analysis 2.4</a>).  </p> </section> <section id="CD010957-sec-0073"> <h5 class="title">Adverse effects of treatment</h5> <p>Eight studies measured major bleeding (as defined by ISTH, <a href="./references#CD010957-bbs2-0111" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>) (<a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010957-bbs2-0004" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366(14):1287-97. FermannGJ , ErkensPM , PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban In patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. clinicaltrials.gov/ct2/show/NCT00439777 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAWA , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. Van BellenB , BamberL , Correa De CarvalhoF , PrinsM , WangM , LensingAWA . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. Van BellenB , PrinsM , BamberL , WangM , LensingAWA . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Blood2012;120(21):3419. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. WangY , WangC . Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010957-bbs2-0005" title="BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132 (Suppl 1):2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMPA , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , vanEsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT: Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-36. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMP , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>). There was no clear difference in the rate of major bleeding between participants treated with oral factor Xa inhibitors (95 events/5721 participants) and those treated with conventional anticoagulation (130 events/5726 participants) leading to an OR of 0.71 (95% CI 0.36 to 1.41; 8 studies, 11,447 participants; low‐certainty evidence; <a href="./references#CD010957-fig-0012" title="">Analysis 2.5</a>). Considerable heterogeneity was detected between the studies (I<sup>2</sup> = 79%), likely due to clinical heterogeneity. </p> </section> <section id="CD010957-sec-0074"> <h5 class="title">Health‐related quality of life</h5> <p>Health‐related quality of life was not reported in any of the included studies.</p> </section> <section id="CD010957-sec-0075"> <h5 class="title">Subgroup analysis</h5> <p>For this update, due to the limited number of included studies, subgroup analyses were only possible for participants who received oral factor Xa inhibitors. We performed subgroup analysis by active cancer and different types of factor Xa inhibitors for the outcome of recurrent VTE and major bleeding.  </p> <p>Results of subgroup analyses showed no clear difference in the incidence of recurrent VTE in participants without cancer (OR 0.89, 95% CI 0.68 to 1.17; 6 studies, 9898 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0009" title="">Analysis 2.2</a>) compared to participants with cancer (OR 0.65, 95% CI 0.42 to 1.01; 3 studies, 1518 participants; high‐certainty evidence; <a href="./references#CD010957-fig-0009" title="">Analysis 2.2</a>). The test for subgroup differences did not indicate a difference (P = 0.23). For the subgroup analysis based on the different types of factor Xa inhibitors, there was also no clear difference in the incidence of recurrent VTE when participants received treatment with apixaban (OR 0.86, 95% CI 0.54 to 1.35; 3 studies, 2459 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0013" title="">Analysis 2.6</a>), rivaroxaban (OR 1.14, 95% CI 0.75 to 1.71; 3 studies, 4981 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0013" title="">Analysis 2.6</a>), and edoxaban (OR 0.66, 95% CI 0.48 to 0.92; 2 studies, 3976 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0013" title="">Analysis 2.6</a>) compared with conventional anticoagulation. The test for subgroup differences did not indicate a difference (P = 0.13).  </p> <p>Subgroup analysis of the incidence of major bleeding in participants without cancer (OR 0.45, 95% CI 0.19 to 1.06; 6 studies, 10,152 participants; low‐certainty evidence; <a href="./references#CD010957-fig-0012" title="">Analysis 2.5</a>) versus participants with cancer (OR 1.51, 95% CI 0.84 to 2.71; 2 studies, 1295 participants; low‐certainty evidence; <a href="./references#CD010957-fig-0012" title="">Analysis 2.5</a>) suggested a possible subgroup difference (test for subgroup differences: P = 0.02). Due to the limited number of studies in this analysis, and as CIs overlap, this should be interpreted with caution. When analysed according to different types of factor Xa inhibitors, there was no clear difference in the incidence of major bleeding between apixaban and conventional anticoagulation (OR 0.36, 95% CI 0.07 to 1.91; 3 studies, 2503 participants; low‐certainty evidence; <a href="./references#CD010957-fig-0014" title="">Analysis 2.7</a>), or between edoxaban and conventional anticoagulation (OR 1.44, 95% CI 0.80 to 2.58; 2 studies, 3976 participants; low‐certainty evidence; <a href="./references#CD010957-fig-0014" title="">Analysis 2.7</a>). However, when treated with rivaroxaban, participants had a lower incidence of major bleeding compared to those treated with conventional anticoagulation (OR 0.49, 95% CI 0.31 to 0.79; 3 studies, 4968 participants; low‐certainty evidence; <a href="./references#CD010957-fig-0014" title="">Analysis 2.7</a>). The test for subgroup differences indicated a possible difference (P = 0.01). Due to the limited number of studies in this analysis, and as CIs overlap, this should be interpreted with caution.  </p> </section> <section id="CD010957-sec-0076"> <h5 class="title">Sensitivity analysis</h5> <p>We performed sensitivity analysis by excluding studies we judged to be at high risk of bias (<a href="./references#CD010957-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):18. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):1159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. In: Canadian Journal of Cardiology. Vol. 30. 2014:S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in therapeutic range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the AMPLIFY trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134 (Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>). Based on the available data, only sensitivity analyses of oral factor Xa inhibitors for PE in the incidence of recurrent VTE and major bleeding were possible. The results showed that oral factor Xa inhibitors versus conventional anticoagulation made no clear difference in reducing the incidence of recurrent VTE (OR 0.78, 95% CI 0.54 to 1.14; 6 studies, 8992 participants; moderate‐certainty evidence; <a href="./references#CD010957-fig-0015" title="">Analysis 2.8</a>) and major bleeding (OR 0.91, 95% CI 0.42 to 1.97; 6 studies, 8979 participants; low‐certainty evidence; <a href="./references#CD010957-fig-0016" title="">Analysis 2.9</a>). The results of the sensitivity analyses are consistent with the results of <a href="./references#CD010957-fig-0009" title="">Analysis 2.2</a> and  <a href="./references#CD010957-fig-0012" title="">Analysis 2.5</a>, which indicates that the results are robust. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010957-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010957-sec-0077"></div> <p>We included an additional five studies for this update, bringing the total to 10 included studies involving 13,073 participants. Two studies investigated an oral DTI (dabigatran) and eight studies investigated oral factor Xa inhibitors (three rivaroxaban, three apixaban, and two edoxaban). Overall the studies were of good methodological quality. The certainty of the evidence was moderate or low. </p> <section id="CD010957-sec-0078"> <h3 class="title" id="CD010957-sec-0078">Summary of main results</h3> <section id="CD010957-sec-0079"> <h4 class="title">Recurrent pulmonary embolism</h4> <p>Moderate‐certainty evidence showed no clear difference between both oral DTIs and factor Xa inhibitors compared to conventional anticoagulation in preventing recurrent pulmonary embolism (PE). We downgraded the certainty of the evidence by one level for imprecision.  </p> </section> <section id="CD010957-sec-0080"> <h4 class="title">Recurrent venous thromboembolism</h4> <p>Moderate‐certainty evidence showed no clear difference between oral DTIs and conventional anticoagulation in the prevention of recurrent venous thromboembolism (VTE) during treatment, indicating that neither was more nor less effective. We downgraded the certainty of the evidence by one level for imprecision. </p> <p>Similarly, for factor Xa inhibitors, moderate‐certainty evidence showed no clear difference between factor Xa inhibitors and conventional anticoagulation in preventing recurrent VTE, indicating that neither was more nor less effective. We downgraded the certainty of the evidence by one level for imprecision.  </p> <p>Subgroup analyses showed no clear difference in the incidence of recurrent VTE between participants with and without cancer, and between participants who received different types of factor Xa inhibitors. Given the limited number of studies providing data in each subgroup, this may reflect a lack of information. More included studies may change the evidence in the future. </p> </section> <section id="CD010957-sec-0081"> <h4 class="title">Deep vein thrombosis</h4> <p>Moderate‐certainty evidence showed no clear difference between both oral DTIs and factor Xa inhibitors compared to conventional anticoagulation in preventing deep vein thrombosis (DVT). We downgraded the certainty of the evidence by one level for imprecision. </p> </section> <section id="CD010957-sec-0082"> <h4 class="title">All‐cause mortality</h4> <p>No study measured all‐cause mortality in participants treated with oral DTIs. Moderate‐certainty evidence showed no clear difference between oral factor Xa inhibitors and conventional therapy in preventing all‐cause mortality. We downgraded the certainty of the evidence by one level for imprecision. </p> </section> <section id="CD010957-sec-0083"> <h4 class="title">Major bleeding</h4> <p>Moderate‐certainty evidence indicated no clear difference between oral DTIs and conventional anticoagulation in major bleeding. We downgraded the certainty of the evidence by one level for imprecision. For factor Xa inhibitors, low‐certainty evidence showed no clear difference between factor Xa inhibitors and conventional anticoagulation in preventing major bleeding. We downgraded the certainty of the evidence by one level for serious inconsistency due to clinical heterogeneity and by one level for imprecision.  </p> <p>Subgroup analyses suggested possible subgroup differences in the incidence of major bleeding between participants without cancer versus those with cancer, and between participants receiving different types of factor Xa inhibitors. Due to the limited number of studies in the subgroups, and as CIs overlap, this should be interpreted with caution. More included studies may change the evidence in the future.  </p> <p>Health‐related quality of life was not reported in the included studies.</p> </section> </section> <section id="CD010957-sec-0084"> <h3 class="title" id="CD010957-sec-0084">Overall completeness and applicability of evidence</h3> <p>This review assessed whether long‐term treatment with oral anticoagulants – DTIs and factor Xa inhibitors – reduced the rate of recurrent PE, recurrent VTE, DVT, all‐cause mortality, and major bleeding in people with PE. Two studies tested DTIs and eight studies tested factor Xa inhibitors within similar study populations. The included studies analysed and reported all of our outcomes of interest, except for health‐related quality of life. Heterogeneity was high for major bleeding in the studies testing factor Xa inhibitors. As expected, this is likely due to clinical heterogeneity, because included studies varied in factor Xa inhibitors (three apixaban, three rivaroxaban, two edoxaban), comparators (six warfarin, two dalteparin), and treatment duration (three months (one study), five and a half months (one study), six months (two studies), 12 months (four studies)).  </p> <p>For this update, we performed subgroup analyses for active cancer and different types of factor Xa inhibitors. Limited data indicated no clear difference in the incidence of recurrent VTE between participants with and without cancer, and between participants who received different types of factor Xa inhibitors. For major bleeding, both subgroup analyses (i.e. of people experiencing PE with versus without cancer, and subgroups of different types of factor Xa inhibitors) suggested possible subgroup differences. Bleeding risk is an important consideration when using DOACs for cancer patients, particularly in patients with gastrointestinal malignancies (<a href="./references#CD010957-bbs2-0119" title="ThapaN , ShatzelJ , DelougheryTG , OlsonSR . Direct oral anticoagulants in gastrointestinal malignancies: is the convenience worth the risk?Journal of Gastrointestinal Oncology2019;10(4):807-9.">Thapa 2019</a>). A systematic review and meta‐analysis of the <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a> and <a href="./references#CD010957-bbs2-0035" title="EUCTR2012-005589-37-GB. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012-005589-37-GB (first received 8 February 2013). YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology2014;32(32):Suppl 1. YoungA , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). Journal of Clinical Oncology2018;36(20):2017-23. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130 (Suppl 1):[no pagination]. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140(Suppl 1):S172-3. ">SELECT‐D 2018</a> studies suggested that the risk of major bleeding in cancer patients was approximately doubled when using DOACs compared with LMWH (<a href="./references#CD010957-bbs2-0097" title="LiA , GarciaDA , LymanGH , CarrierM . Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer-associated thrombosis (CAT): a systematic review and meta-analysis. Thrombosis Research2019;173:158-63.">Li 2019</a>). For factor Xa inhibitors, while efficacy with apixaban, edoxaban, and rivaroxaban versus dalteparin has been consistent in the treatment of cancer‐associated VTE, one study showed heterogeneity is evident with respect to major gastrointestinal bleeding, with an increased risk with edoxaban and rivaroxaban but not apixaban (<a href="./references#CD010957-bbs2-0056" title="AthanazioRA , CeresettoJM , Marfil RiveraLJ , Cesarman-MausG , GalvezK , MarquesMA , et al. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective. Clinical and Applied Thrombosis/Hemostasis2022;28:10760296221082988. [DOI: 10.1177/10760296221082988]">Athanazio 2022</a>). All of these results are based on limited evidence; more evidence is needed to confirm these conclusions in the future. </p> <p>We were unable to perform subgroup analyses for other factors because of the lack of participant‐level data. More evidence is needed, as these analyses might be important to guide clinical management in people with different risk factors for PE. </p> <p>Although many consider DVT and PE to be manifestations of the same disorder, we elected to study these two conditions separately as there is evidence of clinically significant differences between them. First, the majority of recurrent events occur at the same site as the original thrombosis (in other words, in people presenting with a PE, a recurrent event after treatment is much more likely to be another PE). Second, both oral contraceptive use and Factor V Leiden mutation are more likely to be associated with DVT than PE. Third, lung disease is much more likely to be associated with PE. Consequently, a review on the effectiveness of oral DTIs and factor Xa inhibitors for the long‐term treatment of DVT was published at the same time as the previous version of this review (<a href="./references#CD010957-bbs2-0108" title="RobertsonL , KestevenP . Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD010956. [DOI: 10.1002/14651858.CD010956.pub2]">Robertson 2015b</a>). It has also now been updated (<a href="./references#CD010957-bbs2-0123" title="WangX , MaY , HuiX , LiM , LiJ , TianJ , et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews2023, Issue 4. Art. No: CD010956. [DOI: 10.1002/14651858.CD010956.pub3]">Wang 2023</a>).  </p> <p>We did not find any studies comparing:</p> <p> <ul id="CD010957-list-0011"> <li> <p>one oral DTI versus another oral DTI;</p> </li> <li> <p>one oral factor Xa inhibitor versus another oral factor Xa inhibitor;</p> </li> <li> <p>oral DTI versus oral factor Xa inhibitor.</p> </li> </ul> </p> <p>We identified no additional studies investigating DTIs for this update; therefore, this review cannot provide more evidence for this intervention. Given the recent clinical thinking that DOACs have a class effect, we will pool the results of all DTIs and factor Xa inhibitors in future updates. This may increase the power of the studies, reduce type II errors, and allow any effects to be determined clearly. </p> <p>In 2020, the UK's National Institute for Health and Care Excellence (NICE) measured the cost‐effectiveness of DOACs versus conventional anticoagulation for the treatment of DVT and PE (<a href="./references#CD010957-bbs2-0101" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2020. nice.org.uk/guidance/ng158 (accessed 29 July 2022).">NICE 2020</a>). Assuming that people remain on the same drug in the initial and extended phases of treatment, apixaban was highly cost‐effective both in people with a DVT and people with a PE. Rivaroxaban had the next most favourable effect on major bleeding and generated the second‐highest total quality‐adjusted life years (QALYs). The cost of the two drugs was similar and the difference in total costs was mainly led by differences in the number of bleeding events.  </p> </section> <section id="CD010957-sec-0085"> <h3 class="title" id="CD010957-sec-0085">Certainty of the evidence</h3> <p>We assessed the overall risk of bias as low in eight of 10 included studies, reflecting good methodological quality. We judged two studies to have a high risk of reporting bias. Six of the 10 included studies were open‐label because of the complexity of monitoring international normalised ratio (INR) in the conventional anticoagulation arm. However, all outcomes were assessed by observers who were blinded to the treatment and all safety outcomes were adjudicated by a central independent committee in each included study. We could not investigate publication bias because we could not assess asymmetry in a funnel plot with the limited number of studies included in the meta‐analysis.  </p> <p>For the comparison of oral DTIs versus conventional anticoagulation, we graded the certainty of the evidence as moderate, downgrading by one level for imprecision due to the low number of events. For oral factor Xa inhibitors versus conventional anticoagulation, we downgraded the evidence for recurrent PE, recurrent VTE, DVT, and all‐cause mortality to moderate due to the low number of events. For this comparison, we downgraded the evidence for major bleeding by two levels to low, due to the low number of events and substantial clinical heterogeneity. See <a href="./full#CD010957-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD010957-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD010957-sec-0086"> <h3 class="title" id="CD010957-sec-0086">Potential biases in the review process</h3> <p>The search was as comprehensive as possible, and we are confident that we have included all relevant studies. However, the possibility remains that some relevant trials, particularly in the 'grey' literature (for example, conference proceedings), have been missed. Eight review authors independently performed study selection and data extraction in order to minimise bias in the review process. We strictly adhered to the inclusion and exclusion criteria set out in the protocol in order to limit subjectivity. We performed data collection according to the process suggested by Cochrane. We contacted study authors in an attempt to obtain PE‐specific data. We also followed Cochrane processes as described by <a href="./references#CD010957-bbs2-0081" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a> for assessing the risk of bias. Two of the included studies, <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a>, only reported outcome data of VTE, not separate data for PE, so we took data from a pooled analysis published in an additional report (<a href="./references#CD010957-bbs2-0076" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21.">Goldhaber 2016</a>). This was the best available evidence.   </p> </section> <section id="CD010957-sec-0087"> <h3 class="title" id="CD010957-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>This review assesses the efficacy and safety of oral DTIs and oral factor Xa inhibitors for the long‐term treatment of PE. A similar review by <a href="./references#CD010957-bbs2-0068" title="DentaliF , Di MinnoMN , GianniM , AmbrosinoP , SquizzatoA , AgenoW . Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. Internal and Emergency Medicine2015;10(4):507-14.">Dentali 2015</a> evaluated the difference in the safety and efficacy of DOACs compared to conventional treatment in participants presenting with DVT and with PE. The <a href="./references#CD010957-bbs2-0068" title="DentaliF , Di MinnoMN , GianniM , AmbrosinoP , SquizzatoA , AgenoW . Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. Internal and Emergency Medicine2015;10(4):507-14.">Dentali 2015</a> review included six studies (27,023 participants) and indicated that DOACs appear to have similar efficacy and safety profiles compared to VKAs for people with DVT and PE. <a href="./references#CD010957-bbs2-0068" title="DentaliF , Di MinnoMN , GianniM , AmbrosinoP , SquizzatoA , AgenoW . Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. Internal and Emergency Medicine2015;10(4):507-14.">Dentali 2015</a> focused on both PE and DVT, but did not include some more recent RCTs that are included in this update (<a href="./references#CD010957-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation Journal: Official Journal of the Japanese Circulation Society2015;79(6):1230–6. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010957-bbs2-0003" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(05):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2022;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010957-bbs2-0006" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , NisioMD , MulderFI , EsNV , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S223. MulderFI , Di NisioM , AyC , CarrierM , BoschFTM , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. In: European Respiratory Journal. Vol. 55. 2020:1901697. MulderFI , VanEN , KraaijpoelN , DiNM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-7. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130 (Suppl 1):[no pagination]. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010957-bbs2-0007" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010957-bbs2-0008" title="FrankPW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">MERCURY PE 2018</a>). </p> <p>Fourteen other systematic reviews have assessed the same oral anticoagulants (<a href="./references#CD010957-bbs2-0055" title="AntoniazziS , BerdaiD , ContiV , RobinsonP , RadiceS , ClementiE , et al. Risk of major bleeding with dabigatran versus active controls: a systematic review and meta-analysis. Drug Safety2013;36:818.">Antoniazzi 2013</a>; <a href="./references#CD010957-bbs2-0061" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ2013;347:f5133.">Castellucci 2013</a>; <a href="./references#CD010957-bbs2-0062" title="CohenAT , HamiltonM , MitchellSA , PhatakH , LiuX , Bird A et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One2015;10(12):e0144856.">Cohen 2015</a>; <a href="./references#CD010957-bbs2-0075" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a>; <a href="./references#CD010957-bbs2-0078" title="Gomez-OutesA , Terleira-FernandezAI , LecumberriR , Suarez-GeaML , Vargas-CastrillonE . Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis Research2014;134(4):774-82.">Gómez‐Outes 2014</a>; <a href="./references#CD010957-bbs2-0079" title="Gómez-OutesA , LecumberriR , Suárez-GeaML , Terleira-FernándezAI , MonrealM , Vargas-CastrillónE . Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review. Journal of Cardiovascular Pharmacology and Therapeutics2015;20(5):490-500.">Gómez‐Outes 2015</a>; <a href="./references#CD010957-bbs2-0083" title="HirschlM , KundiM . New oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review with indirect comparisons. Vasa2014;43(5):353-64.">Hirschl 2014</a>; <a href="./references#CD010957-bbs2-0088" title="KangN , SobierajDM . Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thrombosis Research2014;133:1145-51.">Kang 2014</a>; <a href="./references#CD010957-bbs2-0100" title="MoikF , PoschF , ZielinskiC , PabingerI , AyC . Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Research and Practice in Thrombosis and Haemostasis2020;4(4):550-61.">Moik 2020</a>; <a href="./references#CD010957-bbs2-0109" title="SamaranayakeCB , AndersonJ , McCabeC , ZahirSF , W UphamJ , KeirG . Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis. Internal Medicine Journal2022;52(2):272-81.">Samaranayake 2022</a>; <a href="./references#CD010957-bbs2-0110" title="SardarP , ChatterjeeS , MukherjeeD . Efficacy and safety or new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomised controlled trials. Drugs2013;73:1171-82.">Sardar 2014</a>; <a href="./references#CD010957-bbs2-0115" title="SongX , LiuZ , ZengR , ShaoJ , LiuB , ZhengY , et al. Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs). Annals of Translational Medicine2021;9(2):162.">Song 2021</a>; <a href="./references#CD010957-bbs2-0121" title="Van der HuilleT , Den ExterPL , DekkersOM , KlokFA . Effectiveness and safety of novel anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis2014;12:320-8.">Van der Huille 2014</a>; <a href="./references#CD010957-bbs2-0127" title="WuO , MorrisS , LarsenTB , SkjøthF , EvansA , BowrinK , et al. Effectiveness and safety of nonvitamin K oral anticoagulants rivaroxaban and apixaban in patients with venous thromboembolism: a meta-analysis of real-world studies. Cardiovascular Therapeutics2022;2022:2756682.">Wu 2022</a>). However, these reviews focused on people with a VTE, and did not report specific data on the subgroup with a PE. Four reviews indicated that DOACs can decrease the risk of recurrent VTE compared to conventional treatment (<a href="./references#CD010957-bbs2-0100" title="MoikF , PoschF , ZielinskiC , PabingerI , AyC . Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Research and Practice in Thrombosis and Haemostasis2020;4(4):550-61.">Moik 2020</a>; <a href="./references#CD010957-bbs2-0109" title="SamaranayakeCB , AndersonJ , McCabeC , ZahirSF , W UphamJ , KeirG . Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis. Internal Medicine Journal2022;52(2):272-81.">Samaranayake 2022</a>; <a href="./references#CD010957-bbs2-0115" title="SongX , LiuZ , ZengR , ShaoJ , LiuB , ZhengY , et al. Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs). Annals of Translational Medicine2021;9(2):162.">Song 2021</a>; <a href="./references#CD010957-bbs2-0127" title="WuO , MorrisS , LarsenTB , SkjøthF , EvansA , BowrinK , et al. Effectiveness and safety of nonvitamin K oral anticoagulants rivaroxaban and apixaban in patients with venous thromboembolism: a meta-analysis of real-world studies. Cardiovascular Therapeutics2022;2022:2756682.">Wu 2022</a>); seven reviews found that DOACs are associated with less bleeding than conventional treatment (<a href="./references#CD010957-bbs2-0055" title="AntoniazziS , BerdaiD , ContiV , RobinsonP , RadiceS , ClementiE , et al. Risk of major bleeding with dabigatran versus active controls: a systematic review and meta-analysis. Drug Safety2013;36:818.">Antoniazzi 2013</a>; <a href="./references#CD010957-bbs2-0075" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a>; <a href="./references#CD010957-bbs2-0078" title="Gomez-OutesA , Terleira-FernandezAI , LecumberriR , Suarez-GeaML , Vargas-CastrillonE . Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis Research2014;134(4):774-82.">Gómez‐Outes 2014</a>; <a href="./references#CD010957-bbs2-0079" title="Gómez-OutesA , LecumberriR , Suárez-GeaML , Terleira-FernándezAI , MonrealM , Vargas-CastrillónE . Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review. Journal of Cardiovascular Pharmacology and Therapeutics2015;20(5):490-500.">Gómez‐Outes 2015</a>; <a href="./references#CD010957-bbs2-0083" title="HirschlM , KundiM . New oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review with indirect comparisons. Vasa2014;43(5):353-64.">Hirschl 2014</a>; <a href="./references#CD010957-bbs2-0121" title="Van der HuilleT , Den ExterPL , DekkersOM , KlokFA . Effectiveness and safety of novel anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis2014;12:320-8.">Van der Huille 2014</a>; <a href="./references#CD010957-bbs2-0127" title="WuO , MorrisS , LarsenTB , SkjøthF , EvansA , BowrinK , et al. Effectiveness and safety of nonvitamin K oral anticoagulants rivaroxaban and apixaban in patients with venous thromboembolism: a meta-analysis of real-world studies. Cardiovascular Therapeutics2022;2022:2756682.">Wu 2022</a>); one review found that DOACs are associated with lower all‐cause mortality compared with those receiving conventional anticoagulants in people with venous thromboembolism (<a href="./references#CD010957-bbs2-0127" title="WuO , MorrisS , LarsenTB , SkjøthF , EvansA , BowrinK , et al. Effectiveness and safety of nonvitamin K oral anticoagulants rivaroxaban and apixaban in patients with venous thromboembolism: a meta-analysis of real-world studies. Cardiovascular Therapeutics2022;2022:2756682.">Wu 2022</a>). </p> <p>The <a href="./references#CD010957-bbs2-0075" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a> review performed meta‐analysis by brand rather than class of drug and found no difference in recurrent VTE between the two treatment groups. Rivaroxaban was the only drug found to be significantly associated with fewer major bleeding episodes (odds ratio (OR) 0.57, 95% confidence interval (CI) 0.39 to 0.84). All‐cause mortality did not differ between the two treatment groups. </p> <p>The <a href="./references#CD010957-bbs2-0121" title="Van der HuilleT , Den ExterPL , DekkersOM , KlokFA . Effectiveness and safety of novel anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis2014;12:320-8.">Van der Huille 2014</a> review showed no difference between the two treatment groups in terms of recurrent VTE, fatal PE, and all‐cause mortality. However, DOACs were associated with a significantly reduced risk of major bleeding (relative risk (RR) 0.60, 95% CI 0.41 to 0.88) and fatal bleeding (RR 0.36, 95% CI 0.15 to 0.87). </p> <p><a href="./references#CD010957-bbs2-0083" title="HirschlM , KundiM . New oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review with indirect comparisons. Vasa2014;43(5):353-64.">Hirschl 2014</a> found no differences between DOACs and conventional treatment regarding recurrent VTE and death. However, bleeding was reduced by rivaroxaban (RR 0.55, 95% CI 0.38 to 0.81), apixaban (RR 0.31, 95% CI 0.17 to 0.55), and edoxaban (RR 0.81, 95% CI 0.71 to 0.93). </p> <p>The <a href="./references#CD010957-bbs2-0078" title="Gomez-OutesA , Terleira-FernandezAI , LecumberriR , Suarez-GeaML , Vargas-CastrillonE . Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis Research2014;134(4):774-82.">Gómez‐Outes 2014</a> review found no clear difference in the risk of recurrent VTE between the two treatment groups (RR 0.91, 95% CI 0.79 to 1.06), but DOACs were associated with reduced major bleeding (absolute risk difference of ‐0.6%, 95% CI ‐1.0% to ‐0.3%). </p> <p>A network meta‐analysis by <a href="./references#CD010957-bbs2-0088" title="KangN , SobierajDM . Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thrombosis Research2014;133:1145-51.">Kang 2014</a> found that DOACs did not differ in the risk of mortality or recurrent VTE. However, dabigatran was associated with increased major bleeding compared to apixaban (RR 2.69, 95% CI 1.19 to 6.07), and edoxaban also had a higher bleeding rate compared to apixaban (RR 2.74, 95% CI 1.40 to 5.39). </p> <p>The <a href="./references#CD010957-bbs2-0127" title="WuO , MorrisS , LarsenTB , SkjøthF , EvansA , BowrinK , et al. Effectiveness and safety of nonvitamin K oral anticoagulants rivaroxaban and apixaban in patients with venous thromboembolism: a meta-analysis of real-world studies. Cardiovascular Therapeutics2022;2022:2756682.">Wu 2022</a> review included 65 real‐world evidence studies and found that, in people with VTE, rivaroxaban and apixaban are associated with a lower risk of recurrent VTE (rivaroxaban: HR 0.68, 95% CI 0.60 to 0.76; apixaban: HR 0.83, 95% CI 0.73 to 0.93), major bleeding events (rivaroxaban: HR 0.73, 95% CI 0.65 to 0.81; apixaban: HR 0.76, 95% CI 0.68 to 0.85), and all‐cause mortality (HR 0.56, 95% CI 0.39 to 0.80) compared with those receiving conventional anticoagulants. </p> <p>The <a href="./references#CD010957-bbs2-0115" title="SongX , LiuZ , ZengR , ShaoJ , LiuB , ZhengY , et al. Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs). Annals of Translational Medicine2021;9(2):162.">Song 2021</a> review included four RCTs and 14 retrospective studies and found that DOACs decreased the risk of recurrent VTE (RCTs: OR 0.60, 95% CI 0.45 to 0.80; retrospective studies: OR 0.73, 95% CI 0.59 to 0.90) and recurrent DVT (RCTs: OR 0.54, 95% CI 0.36 to 0.80; retrospective studies: OR 0.20, 95% CI 0.06 to 0.63), but not PE recurrence (OR 0.75, 95% CI 0.53 to 1.05), fatal PE (OR 0.87, 95% CI 0.33 to 2.26), and major bleeding events (OR 1.04, 95% CI 0.84 to 1.28) compared with LMWHs in people with cancer.  </p> <p>The <a href="./references#CD010957-bbs2-0109" title="SamaranayakeCB , AndersonJ , McCabeC , ZahirSF , W UphamJ , KeirG . Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis. Internal Medicine Journal2022;52(2):272-81.">Samaranayake 2022</a> review conducted a network meta‐analysis including four RCTs with 2907 participants with venous thromboembolism. They found that the overall risk of recurrent VTE was lower in the DOACs group compared to the dalteparin group (RR 0.63, 95% CI 0.44 to 0.91). There was no statistically significant difference in risk of major bleeding (RR 1.31, 95% CI 0.83 to 2.07) and all‐cause mortality (RR 1.0, 95% CI 0.84 to 1.18) at six months' follow‐up between DOACs and LMWH.  </p> <p>A review by <a href="./references#CD010957-bbs2-0100" title="MoikF , PoschF , ZielinskiC , PabingerI , AyC . Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Research and Practice in Thrombosis and Haemostasis2020;4(4):550-61.">Moik 2020</a> that included four RCTs (with 2894 participants with cancer‐associated VTE) found that DOACs significantly reduced recurrent VTE compared to LMWHs (RR 0.62, 95% CI 0.43 to 0.91), but were associated with a non‐significant increase in major bleeding (RR 1.31, 95% CI 0.83 to 2.08). Mortality risks were comparable between groups (RR 0.99, 95% CI 0.83 to 1.18).  </p> <p>The <a href="./references#CD010957-bbs2-0079" title="Gómez-OutesA , LecumberriR , Suárez-GeaML , Terleira-FernándezAI , MonrealM , Vargas-CastrillónE . Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review. Journal of Cardiovascular Pharmacology and Therapeutics2015;20(5):490-500.">Gómez‐Outes 2015</a> review found that DOACs were associated with lower major bleeding (RR 0.62, 95% CI 0.45 to 0.85), while there was no clear difference in recurrent VTE rate in people receiving DOACs or standard therapy (RR 0.91, 95% CI 0.79 to 1.05). </p> <p>A review by <a href="./references#CD010957-bbs2-0062" title="CohenAT , HamiltonM , MitchellSA , PhatakH , LiuX , Bird A et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One2015;10(12):e0144856.">Cohen 2015</a> conducted a network meta‐analysis to compare the efficacy and safety of DOACs for the initial and long‐term treatment of VTE. They found that apixaban was associated with a statistically significantly reduced risk of major bleeding compared with rivaroxaban (RR 0.47, 95% CI 0.36 to 0.61), dabigatran (RR 0.69, 95% CI 0.51 to 0.94), and edoxaban (RR 0.54, 95% CI 0.41 to 0.69). Dabigatran was associated with a significantly lower risk of major bleeding compared with rivaroxaban (RR 0.68, 95% CI 0.53 to 0.87) and edoxaban (RR 0.77, 95% CI 0.60 to 0.99). There were no clear differences between the DOACs with regard to the risk of VTE and related death. </p> <p>The <a href="./references#CD010957-bbs2-0055" title="AntoniazziS , BerdaiD , ContiV , RobinsonP , RadiceS , ClementiE , et al. Risk of major bleeding with dabigatran versus active controls: a systematic review and meta-analysis. Drug Safety2013;36:818.">Antoniazzi 2013</a> review included participants with VTE and atrial fibrillation. Eight studies were included and results showed that the risk of major bleeding was lower in participants treated with dabigatran (RR 0.83, 95% CI 0.78 to 0.97) compared with the control group. </p> <p>The reviews by <a href="./references#CD010957-bbs2-0061" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ2013;347:f5133.">Castellucci 2013</a>, <a href="./references#CD010957-bbs2-0063" title="CohenAT , HamiltonM , BirdA , MitchellSA , LiS , HorblyukR , et al. Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One2016;11(9):e0163386.">Cohen 2016</a>, <a href="./references#CD010957-bbs2-0110" title="SardarP , ChatterjeeS , MukherjeeD . Efficacy and safety or new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomised controlled trials. Drugs2013;73:1171-82.">Sardar 2014</a>, and <a href="./references#CD010957-bbs2-0122" title="WangKL , Van EsN , CameronC , CastellucciLA , BüllerHR , CarrierM . Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. Heart2019;105(7):545-52.">Wang 2018</a> compared oral anticoagulants and antiplatelet drugs, but the focus was on the secondary prevention of venous thromboembolism rather than treatment.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010957-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010957-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010957-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010957-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral DTIs versus conventional anticoagulation, Outcome 1: Recurrent pulmonary embolism" data-id="CD010957-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Oral DTIs versus conventional anticoagulation, Outcome 1: Recurrent pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral DTIs versus conventional anticoagulation, Outcome 2: Recurrent venous thromboembolism" data-id="CD010957-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Oral DTIs versus conventional anticoagulation, Outcome 2: Recurrent venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral DTIs versus conventional anticoagulation, Outcome 3: Deep vein thrombosis" data-id="CD010957-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Oral DTIs versus conventional anticoagulation, Outcome 3: Deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral DTIs versus conventional anticoagulation, Outcome 4: Major bleeding" data-id="CD010957-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Oral DTIs versus conventional anticoagulation, Outcome 4: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 1: Recurrent pulmonary embolism" data-id="CD010957-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 1: Recurrent pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 2: Recurrent venous thromboembolism" data-id="CD010957-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 2: Recurrent venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 3: Deep vein thrombosis" data-id="CD010957-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 3: Deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 4: All‐cause mortality" data-id="CD010957-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 4: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 5: Major bleeding" data-id="CD010957-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 5: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 6: Recurrent venous thromboembolism (subgroup analysis based on different types of factor Xa inhibitors)" data-id="CD010957-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 6: Recurrent venous thromboembolism (subgroup analysis based on different types of factor Xa inhibitors) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 7: Major bleeding (subgroup analysis based on different types of factor Xa inhibitors)" data-id="CD010957-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 7: Major bleeding (subgroup analysis based on different types of factor Xa inhibitors) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 8: Recurrent venous thromboembolism (sensitivity analysis by including only studies at low risk of bias)" data-id="CD010957-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 8: Recurrent venous thromboembolism (sensitivity analysis by including only studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010957-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/urn:x-wiley:14651858:media:CD010957:CD010957-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 9: Major bleeding (sensitivity analysis by including only studies at low risk of bias)" data-id="CD010957-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_t/tCD010957-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 9: Major bleeding (sensitivity analysis by including only studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/media/CDSR/CD010957/image_n/nCD010957-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010957-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation for the treatment of pulmonary embolism</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation for the treatment of pulmonary embolism</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with a pulmonary embolism, confirmed by standard imaging techniques<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> oral DTIs<br/><b>Comparison:</b> conventional anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with conventional anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oral DTI</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent PE</b><sup>a</sup> </p> <p> </p> <p>Follow‐up: </p> <p>6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.02</b><br/>(0.50 to 2.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1602<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data from <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(10 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b><sup>c</sup> </p> <p> </p> <p>Follow‐up: </p> <p>6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.93</b><br/>(0.52 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1602<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data from <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(16 to 50) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><sup>d</sup> </p> <p> </p> <p>Follow‐up: </p> <p>6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.79</b><br/>(0.29 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1602<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data from <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(3 to 23) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> did not report on all‐cause mortality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><sup>e</sup> </p> <p> </p> <p>Follow‐up: </p> <p>6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.50</b><br/>(0.15 to 1.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1527<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The data from <a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(2 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010957-bbs2-0009" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010957-bbs2-0010" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , FeuringM , HantelS . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130 (Suppl 2):A18594. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal2014;35 (Suppl 1):990. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-cover and RE-cover II. Blood2013;122(21):2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood2013;122(21):212. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS , KakkarAK , SchellongSM , GoldhaberSZ , HenryE , MismettiP , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):Abstract 205. ">RE‐COVER II 2014</a> did not measure health‐related quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CTPA:</b> computed tomographic pulmonary angiography; <b>DVT</b> : deep vein thrombosis; <b>ISTH</b> : International Society on Thrombosis and Haemostasis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>V/Q:</b> ventilation/perfusion; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate, the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited, the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Confirmed by V/Q lung scanning, pulmonary angiography, or CTPA<br/><sup>b</sup>We downgraded one level for imprecision due to the low number of events. The possibility of publication bias is not excluded but we did not consider it sufficient to downgrade the certainty of evidence.<br/><sup>c</sup>VTE includes clinically overt DVT and PE. Clinically overt DVT, confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, proximal compression ultrasound); or clinically overt PE, confirmed by V/Q lung scanning, pulmonary angiography, or CTPA.<br/><sup>d</sup>Clinically overt DVT confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, proximal compression ultrasound). <br/><sup>e</sup>As defined by the ISTH (<a href="./references#CD010957-bbs2-0111" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>): 1. Fatal bleeding, and/or 2. symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra‐articular or pericardial, or intramuscular with compartment syndrome, and/or 3. bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or packed red cells. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation for the treatment of pulmonary embolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010957-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation for the treatment of pulmonary embolism</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Oral factor Xa inhibitors versus conventional anticoagulation for the treatment of pulmonary embolism</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with a pulmonary embolism, confirmed by standard imaging techniques<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> oral factor Xa inhibitors<br/><b>Comparison:</b> conventional anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk with conventional<b> </b> anticoagulation </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oral factor Xa inhibitors</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent PE</b><sup>a</sup> </p> <p> </p> <p>Follow‐up: </p> <p>0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.92</b><br/>(0.66 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8186<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b </sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(12 to 23) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b><sup>c</sup> </p> <p> </p> <p>Follow‐up: </p> <p>0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.83</b><br/>(0.66 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,416<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 of 8 studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/>(21 to 33) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><sup>d</sup> </p> <p> </p> <p>Follow‐up: </p> <p>5 days to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.77</b><br/>(0.48 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8151<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/>(5 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p> </p> <p>Follow‐up: </p> <p>0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.16</b><br/>(0.79 to 1.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4817<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(16 to 35) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><sup>e</sup> </p> <p> </p> <p>Follow‐up: </p> <p>0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.71</b><br/>(0.36 to 1.41)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,447<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 of 8 studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(8 to 32) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies did not measure health‐related quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CTPA:</b> computed tomographic pulmonary angiography; <b>DVT:</b> deep vein thrombosis; <b>ISTH:</b> International Society on Thrombosis and Haemostasis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>V/Q:</b> ventilation/perfusion; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate, the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited, the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate, the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Confirmed by V/Q lung scanning, pulmonary angiography, or CTPA.<br/><sup>b</sup>We downgraded one level for imprecision due to the low number of events. The possibility of publication bias is not excluded but we did not consider it sufficient to downgrade the certainty of evidence.<br/><sup>c</sup>VTE includes clinically overt DVT and PE. Clinically overt DVT, confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, proximal compression ultrasound); or clinically overt PE, confirmed by V/Q lung scanning, pulmonary angiography, or CTPA.<br/><sup>d</sup>Clinically overt DVT confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, proximal compression ultrasound). <br/><sup>e</sup>As defined by the ISTH (<a href="./references#CD010957-bbs2-0111" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>): 1. Fatal bleeding, and/or 2. symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra‐articular or pericardial, or intramuscular with compartment syndrome, and/or 3. bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or packed red cells.<br/><sup>f</sup>We downgraded one level for serious inconsistency (I<sup>2</sup> = 79% due to clinical heterogeneity). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation for the treatment of pulmonary embolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/full#CD010957-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010957-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral DTIs versus conventional anticoagulation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Recurrent pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Recurrent venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral DTIs versus conventional anticoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010957-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Recurrent pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.66, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Recurrent venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.66, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Non‐cancer associated pulmonary embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Cancer associated pulmonary embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.42, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.48, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.36, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Non‐cancer associated pulmonary embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.19, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Cancer associated pulmonary embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.84, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Recurrent venous thromboembolism (subgroup analysis based on different types of factor Xa inhibitors) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.66, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Apixaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.54, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Rivaroxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.75, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 Edoxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.48, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Major bleeding (subgroup analysis based on different types of factor Xa inhibitors) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.36, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Apixaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.07, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Rivaroxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.31, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 Edoxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.80, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Recurrent venous thromboembolism (sensitivity analysis by including only studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.54, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Major bleeding (sensitivity analysis by including only studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.42, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010957.pub3/references#CD010957-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010957.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010957-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010957-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010957-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010957-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD010957-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD010957-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD010957-note-0007">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010957-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010957\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010957\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010957\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010957\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010957\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010957.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010957.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010957.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010957.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010957.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715535349"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010957.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715535353"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010957.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d89760fab9374',t:'MTc0MDcxNTUzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 